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ABSTRACT
Heart failure and diabetes is a common combination. In the presence of diabetes heart failure prognosis becomes 
very serious, but the exact reasons are not understood. A limitation while interpreting existing data is that they 
usually derive from heart failure populations in whom patients with diabetes are selected, in small proportions and 
their characteristics are less well explored. This explains why it still is uncertain which factors are prognostically 
most important. Moreover, whether diabetes impacts prognosis differently in heart failure with preserved (HFpEF), 
mid-range (HFmrEF) and reduced (HFrEF) ejection fraction has not been fully investigated. In these respects 
analyses of nationwide registry based heart failure populations may provide valuable information. 
Aims  
To study the combination of diabetes and heart failure in a contemporary, unselected heart failure population by 
analysing
1. Demographic characteristics and long-term prognosis
2. Whether there are differences between women and men in this respect
3. The impact of diabetes in ischaemic versus non-ischaemic heart failure and the role of revascularization
4. The influence of diabetes in different types of heart failure 
Diabetes and heart failure
Of 36 274 patients with clinician judged heart failure registered in the Swedish Heart Failure Registry (SwedeHF) 
from specialist care between 2003-2011, 24% had reported diabetes. The patients were followed for mortality until 
September 2011. Diabetes was an independent predictor of mortality particularly in the age group ≤65 years (OR 
1.61; 95% CI 1.36-1.92) compared to patients >80 years (OR 1.46; 95% CI 1.31-1.62). This pattern was apparent 
despite a more extensive pharmacological treatment in patients with diabetes and although a similar left ventricular 
and renal function in patients with and without diabetes.  
Influence of diabetes in women and men with heart failure
Women represented 39% of the SwedeHF population irrespective of diabetes state. In the presence of diabetes the 
mortality risk increased by 70% in women (OR 1.72; 95% CI 1.53-1.94) and by 40% in men (OR 1.47; 95% CI 
1.34-1.61), but age-adjusted survival did not differ between women and men with diabetes (log-rank p=0.18). In 
contrast women without diabetes had a better prognosis than their male counterparts (log-rank p<0.0001). Women 
with diabetes and heart failure, in particular those ≤65 years, had a risk factor profile resembling that of men with a 
high prevalence of ischaemic heart disease and hypertension. 
Ischaemic versus non-ischaemic heart failure and the role of previous revascularization in diabetes 
The impact of diabetes in ischaemic versus non-ischaemic heart failure was studied in 35 163 patients in SwedeHF. 
A particularly high proportion of diabetes was reported in patients with ischaemic compared with non-ischaemic 
heart failure (31% versus 18%). As many as 90% of patients with diabetes had at least one preventable comorbidity 
of which ischaemic heart disease and hypertension were most frequent. Diabetes had a negative impact on survival 
irrespective of whether the aetiology was ischaemic or non-ischaemic. The highest mortality was, however, seen in 
those with ischaemic aetiology (adjusted HR 1.41; 95% CI 1.33-1.50 versus 1.30; 1.20-1.41). A history of coronary 
revascularization was associated with better survival after propensity score adjustment. Still revascularisation had 
only been performed in half the diabetes patients. 
Impact of diabetes in heart failure with different left ventricular function
Among 30 696 patients in SwedeHF followed until December 2014, 22% had HFpEF, 21% HFmrEF and 57% 
HFrEF. The prevalence of diabetes was similar across the groups (24-25%). In the presence of diabetes the clinical 
characteristics of patients with HFmrEF resembled those in the HFrEF group. Diabetes had a negative impact on 
mortality with the highest risk increase in patients with HFmrEF (HR 1.51; 95% CI 1.39-1.65) and HFrEF (HR 1.46; 
95% CI 1.39-1.54). A similar impact although slightly less apparent was seen in patients with HFpEF (HR 1.32; 
95% CI 1.22-1.43). 
Conclusion 
From these analyses in a nationwide, contemporary heart failure population it can be concluded that diabetes 
is present in 24% to 31% of the patients. The combination of heart failure and diabetes compromises survival 
irrespective of sex, heart failure aetiology or heart failure entity. The increased mortality risk varies between 30-70% 
depending on age, sex and aetiology. Systolic dysfunction and ischaemic heart disease are associated with the worst 
prognosis. Although associated with an improved longevity coronary revascularization seems to be underused. The 
worse prognosis associated with diabetes may partly be explained by a heavier comorbidity burden but the existence 
of a diabetes cardiomyopathy cannot be ruled out. In the future improved attention of these patients are needed and 
studies searching for a better understanding of underlying mechanisms opening for novel treatment modalities.
          Diabetes Mellitus and Heart Failure
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SAMMANFATTNING
Hjärtsvikt och diabetes är en vanlig kombination. I närvaro av diabetes är hjärtsviktsprognosen mycket allvarlig men 
bakomliggande orsaker är inte helt klarlagda. Tolkningen av tillgängliga data försvåras av att de vanligtvis härrör 
från hjärtsviktspopulationer där patienter med diabetes är selekterade, fåtaliga och bristfälligt karaktäriserade. Detta 
förklarar varför det fortfarande är oklart vilka faktorer som är prognostiskt viktigast. Vidare, är det ofullständigt 
utrett hur diabetes påverkar prognosen vid hjärtsvikt med bevarad (HFpEF), lätt sänkt (HFmrEF) och sänkt (HFrEF) 
ejektionsfraktion. Nationella registerbaserade hjärtsviktspopulationer kan i dessa avseenden tillföra värdefull 
information. 
Syfte
Att studera kombinationen diabetes och hjärtsvikt i en nutida, stor oselekterad hjärtsviktspopulation genom att 
analysera
1. Demografiska karakteristika och långtidsprognos
2. Huruvida det finns olikheter mellan kvinnor och män i detta hänseende
3. Betydelsen av diabetes vid ischemisk och icke-ischemisk hjärtsvikt och betydelsen av revaskularisering
4. Betydelsen av diabetes vid olika typer av hjärtsvikt
Diabetes och hjärtsvikt
Av 36 274 patienter med kliniskt diagnosticerad hjärtsvikt registrerade i det Svenska hjärtsviktregistret (SwedeHF; 
RiksSvikt) från specialistsjukvården mellan 2003-2011, hade 24% rapporterad diabetes. Patienterna följdes avseende 
dödlighet till och med september 2011. Diabetes var en oberoende prediktor för mortalitet, särskilt i åldersgruppen 
≤65 år (OR 1.61; 95% CI 1.36-1.92) jämfört med patienter >80 år (OR 1.46; 95% CI 1.31-1.62). Detta mönster sågs 
trots mer extensiv läkemedelsbehandling hos patienter med diabetes och liknande vänsterkammar- och njurfunktion 
hos patienter med och utan diabetes.
Betydelsen av diabetes hos kvinnor och män med hjärtsvikt
Kvinnor utgjorde 39% av RiksSvikt-populationen oavsett diabetesstatus. I närvaro av diabetes ökade risken för död 
med 70% hos kvinnorna (OR 1.72; 95% CI 1.53-1.94) och med 40% hos männen (OR 1.47; 95% CI 1.34-1.61), 
men den åldersjusterade överlevnaden skiljde sig inte åt mellan kvinnor och män med diabetes (log-rank p=0.18). I 
motsats hade kvinnor utan diabetes en bättre prognos än deras manliga motsvarigheter (log-rank p<0.0001). Kvinnor 
med diabetes och hjärtsvikt hade en riskfaktorprofil som liknade den hos männen med högre förekomst av ischemisk 
hjärtsjukdom och hypertoni, särskilt tydlig hos de under 66 år.  
Ischemisk jämfört med icke-ischemisk hjärtsvikt och betydelsen av revaskularisering vid diabetes
Betydelsen av ischemisk och icke-ischemisk hjärtsvikt studerades hos 35 163 patienter i RiksSvikt. En särskilt stor 
andel diabetes förekom hos patienter med ischemisk jämfört med icke-ischemisk hjärtsvikt (31% vs. 18%). Hela 
90% av patienterna med diabetes hade minst en förebyggbar komorbiditet bland vilka ischemisk hjärtsjukdom och 
hypertoni var de vanligaste. Diabetes hade en negativ inverkan på överlevnad oavsett om hjärtsviktsorsaken var 
ischemisk eller icke-ischemisk. Den högsta dödligheten sågs dock hos de med ischemisk etiologi (justerad HR 
1.41; 95% CI 1.33-1.50 jfrt.1.30; 1.20-1.41). Tidigare genomförd revaskularisering var kopplat till en förbättrad 
överlevnad efter justering med propensity score men revaskularisering hade bara utförts hos hälften av patienterna 
med diabetes.
Betydelsen av diabetes vid hjärtsvikt med olika vänsterkammarfunktion
Av 30 696 patienter i RiksSvikt följda till december 2014 hade 22% HFpEF, 21% HFmrEF och 57% HFrEF. 
Förekomsten av diabetes var densamma i de tre grupperna (24-25%). I närvaro av diabetes liknade kliniska 
karakteristika hos HFmrEF dem hos HFrEF gruppen. Diabetes hade en negativ inverkan på dödlighet med den 
högsta risken hos patienter med HFmrEF (HR 1.51; 95% CI 1.39-1.65) och HFrEF (HR 1.46; 95% CI 1.39-1.54). 
En liknande inverkan, om än något mindre uttalad, sågs hos patienter med HFpEF (HR 1.32; 95% CI 1.22-1.43). 
Konklusion
Baserat på analyser av en nationell samtida hjärtsviktspopulation kan man konkludera att diabetes förekommer 
hos 24% till 31% av patienterna. Kombinationen hjärtsvikt och diabetes påverkar överlevnaden negativt 
oavsett kön, hjärtsviktsorsak eller hjärtsviktstyp. Den ökade risken för död varierar i storleksordningen 30-
70% beroende på ålder, kön och etiologi. Systolisk dysfunktion och ischemisk hjärtsjukdom är associerat med 
en sämre prognos. Koronar revaskularisering är kopplat till en förbättrad överlevnad men ter sig underanvänd. 
Den av diabetes försämrade prognosen kan delvis förklaras av en större samsjuklighetsbörda men förekomsten av 
en specifik diabeteskardiomyopati kan inte uteslutas. I framtiden behövs en ökad uppmärksamhet kring diabetes 
och hjärtsvikt samt studier som ger en bättre förståelse för bakomliggande mekanismer och som kan öppna nya 
behandlingsmodaliteter.
Isabelle Johansson
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LIST OF ABBREVIATIONS
ACEi Angiotensin-converting enzyme inhibitor
ADA American Diabetes Association
AGEs Advanced Glycated End-products
ARB Angiotensin receptor blocker
ARNI Angiotensin receptor neprilysin inhibitor
BMI Body mass index
CHARM Candesartan Heart failure-Assessment of Reduction in Mortality and morbidity trial
CG Cockroft-Gault
CI Confidence Interval
CIBIS-II Cardiac Insufficiency Bisoprolol Study II
CKD Chronic Kidney Disease
CONSENSUS Cooperative North Scandinavian Enalapril Survival Study
COPERNICUS Carvedilol Prospective Randomized Cumulative Survival
DCCT Diabetes Control and Complications Trial
DM Type 2 diabetes
DPP-4 Dipeptidylpeptisase-4
EMPA-REG Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients
EMPHASIS-HF Eplerenone in Mild Patients Hospitalization and Survival Study in heart Failure
ESC European Society of Cardiology
eGRF estimated Glomerular Filtration Rate
FFA Free Fatty Acids
GLP-1 Glucagon-like peptide-1
HF Heart Failure
Hb Haemoglobin
HFmrEF Heart Failure mid-range Ejection Fraction
HFpEF Heart Failure preserved Ejection Fraction
HFrEF Heart Failure reduced Ejection Fraction
HR Hazard ratio
iDCM Idiopathic Dialated Cardiomyopathy
IHD Ischaemic Heart Disease
LVEF Left Ventricular Ejection Fraction
LEADER Liraglutide Effect of Cardiovascular Outcome Results
MERIT-HF Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure
MDRD Modification of Diet in Renal Disease
MRA Mineralocorticoid receptor antagonist
NT pro-BNP N-Terminal Pro-Natriuretic Peptide
NYHA New York Heart Association
OR Odds ratio
PARADIGM-HF Prospective Comparison of ARNI With ACEi to Determine Impact on Global Mortality 
in Heart Failure
RAAS Renin angiotensin aldosterone system
RALES Randomized Aldactone Evaluation Study
SD Standard deviation
SGLT-2 Sodium-glucose cotransporter-2
SOLVD Studies of Left Ventricular Dysfunction trial
SUSTAIN-6 Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes
SwedeHF The Swedish Heart Failure Registry (RiksSvikt)
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INTRODUCTION
Diabetes Mellitus
History
The earliest known notes of diabetes are more than 3500 years old, written on the Egyptian 
Ebers Papyrus dated at 1552 B.C. where the physician Hesy-Ra mentions the symptom of excess 
urination (Figure 1). Around the same time, the Indian physician Charaka identified a disease 
called ‘madhumea’ or ‘honey urine’ that attracted flies and ants. The Greek Apollonius of Memphis 
is usually credited the term ‘Diabetes’ (Greek ‘diabainen’) meaning ‘to pass through’ used for 
the first time 230 B.C. referring to a disease that provokes incessant thirst and immoderate loss 
of urine. Ancient Greek, Chinese, Egyptian, Indian and Persian physicians had noticed the sweet 
taste of urine and in 1675 Willis added the Latin word mellitus (melli’tus) meaning ‘sweetened 
like honey’ referring to the urinary taste. In 1776 Dobson managed to measure urinary glucose 
in such patients and found it increased.1 The earliest detailed reference to diabetes dates back 
to the 2nd century when the Greek Aretaeus of Cappadocia described symptoms and the course 
of the disease but it was not until 1552 the text was published in Venice as a first Latin edition. 
The understanding of the involvement of the pancreas came around 1889 when Von Mering and 
Minkowski noted that dogs deprived their pancreas, developed symptoms typical for diabetes.2,3 
In 1869 Langerhans discovered “islands of richly innervated, clear cells that stained differently 
than the rest of the pancreas”. Laguesse confirmed his findings in 1893 suggesting there were 
secretory glands within the pancreas and designated them the name ‘islets of Langerhans’. De 
Meyer in 1910 termed the pancreatic secretion lacking in diabetes ‘insulin’ to denote its origin 
from the insulae of Langerhans.4 Still it was not until 
1921 that Banting, Best and Macleod showed that 
the administration of extract from pancreatic island 
cells to pancreatectomised dogs, counteracted the 
hyperglycaemia that characterises diabetes. The first 
patient, who was treated with the purified insulin, was 
the 13-year old Leonard Thompson in Canada.5 
That there may be different forms of diabetes was 
hypothesised during the 1920s. In 1926, MacLean 
suggested the distinction between ‘hepatic glycosuria’ 
and ‘true diabetes’ and in the 1930s Himsworth, 
trying to understand why hyperglycaemia occurred, 
postulated that it relates either to insulin deficiency 
or insulin insensitivity.6 Oral glucose lowering agents 
were introduced in the 1950s with sulfonylureas and 
biguanides and 50 years thereafter other classes of 
glucose lowering drugs entered the market most 
recently incretins (Glucagon-like peptide-1 (GLP-1) 
receptor antagonists and Dipeptidylpeptidase (DPP-
4) inhibitors) and Sodium glucose transport receptor 
inhibitors (SGLT-2). Until the discovery of insulin 
patients, especially those with type 1 diabetes, died 
shortly after the onset of the disease. Figure 1. Ebers Papyrus.
          Diabetes Mellitus and Heart Failure
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Definition and classification of diabetes mellitus
Diabetes is a metabolic disorder characterized by hyperglycaemia with disturbances in 
carbohydrate, fat and protein metabolism due to defects in insulin secretion, insulin action 
or both.7 Diabetes causes microvascular complications potentially leading to dysfunction 
or failure of important organs including retinopathy (causing blindness), nephropathy 
(causing renal failure) and neuropathy (causing autonomic dysfunction and paraesthesia).7 
In parallel, the metabolic perturbations increase the risk of macrovascular complications 
leading to coronary artery, peripheral artery and cerebrovascular disease.7 The World Health 
Organization (WHO) has issued guidelines for the diagnosis of diabetes mellitus since 1965 
but the first widely accepted classification of diabetes including its pre-states, was introduced 
in 1979 by the National Diabetes Data Group followed by the WHO in 1980. The classification 
has since been slightly modified by the WHO and the American Diabetes Association (ADA) 
with the most recent recommendations issued in 2006 plus 2011,7,8 and 2017 respectively.9 
Plasma glucose estimation in fasting and post-prandial state, or haemoglobin A1c (HbA1c; 
reflecting the average glycaemia during the last 2-3 months, the normal life span of a red 
blood cell) constitutes the basis of diagnostic criteria as outlined in Table 1.7-9 The threshold 
for the diagnosis, regardless of method, is primarily determined by the level above which 
diabetes retinopathy start to develop.8,9 Of note, impaired glucose tolerance is usually present 
several years before diagnosis, during which the risk of macrovascular complications is 
already present.10 
Based on the aetiological background WHO has, as outlined in Table 2, sub-divided diabetes 
into four main groups: type 1, type 2, other specific types and gestational diabetes.7 Although 
each type is important this thesis focuses on type 2 diabetes, which will be referred to as 
diabetes throughout the rest of the thesis.
Table 1. Diagnostic criteria of diabetes and other dysglycaemic categories according to the WHO 
20067, 20118 and the ADA 201411 definitions. Glucose levels refer to venous plasma measurement.
Dysglycaemic category WHO 20067, 20118 ADA 201411
Diabetes Mellitus
      Fasting plasma glucose ≥7.0 mmol/L (126mg/dL) ≥7.0 mmol/L (126mg/dL)
      2h post load glucose ≥11.1mmol/L (200mg/dL) ≥11.1mmol/L (200mg/dL)
      HbA1c (Mono S)/(IFCC) ≥6.5% / ≥48 mmol/mol ≥6.5% / ≥48 mmol/mol
      Random plasma glucose symptoms + ≥11.1mmol/L (200mg/dL) symptoms + ≥11.1mmol/L (200mg/dL)
Impaired glucose tolerance (IGT)
      Fasting plasma glucose <7.0 mmol/L (126mg/dL) <7.0 mmol/L (126mg/dL)
      2h post load glucose ≥7.8 and <11.1 mmol/L 
(≥140mg/dL and <200mg/dL)
≥7.8 and <11.1 mmol/L 
(≥140mg/dL and <200mg/dL)
Impaired fasting glucose (IFG)
      Fasting plasma glucose 6.1-6.9  mmol/L (110-125 mg/dL) 5.6-6.9  mmol/L (110-125 mg/dL)
      2h post load glucose <7.8 mmol/L (<140 mg/dL) <7.8 mmol/L (<140 mg/dL)
High risk HbA1c - 5.7-6.4% /( 39-47 mmol/mol)
Isabelle Johansson
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Epidemiology
Prevalence - According to the International Diabetes Federation (IDF) the global prevalence 
of diabetes in the adult population approached 9% in 2015 and is, due to ageing populations 
and changes in life style habits, rapidly increasing towards an expected prevalence of 10.4% in 
2040.10 The corresponding proportion in Sweden is somewhat lower, 6.3%.10 The prevalence 
is highly dependent on age, type of investigated population and screening methods. In the 
western societies diabetes is presumed to be undiagnosed in about 40% of all those afflicted.10 
Incidence - The age-standardized, annual incidence of diabetes, reported to be 2.2 and 
2.3/1000 person-years in Dutch men and women respectively, is rather uniform in several 
European countries.12 According to a report from a community in northern Sweden the 
incidence of diabetes is 3-4/1000 inhabitants. It has been stable or slightly decreasing during 
the past 40 years.13,14  
Risk factors – Besides increasing age the most important risk factors for diabetes are excess 
body weight especially abdominal obesity, low physical activity and poor dietary habits. 
In addition ethnicity, family history and a history of gestational diabetes are important.7,9 
Diabetes is often clustering with other risk factors including hypertension, dyslipidaemia, 
insulin resistance and abdominal obesity, usually referred to as the ‘metabolic syndrome’, all 
multiplying the risk of cardiovascular disease.7 
Prognosis 
Apart from microvascular complications, diabetes increases the risk of macrovascular 
complications including various cardiovascular disease manifestations and heart failure by 
two to four times.15 Both micro- and macrovascular complications have decreased as a result 
of an improved, multifactorial risk factor management.16-18 Furthermore, life expectancy 
in patients with diabetes is approaching that of those without, although there is still a gap 
between people with and without this disease.19,20 
Table 2. Four main groups of diabetes classification according to the WHO.7
Type 1 diabetes Accounts for 5-10% of all diabetes and is usually aquired during childhood 
with abrupt onset caused by a cellular-mediated autoimmune destruction of the 
pancreatic β-cells leading to an absolute insulin deficiency and the need of lifelong 
insulin treatment. Latent autoimmune diabetes in adults (LADA) is a similar form 
although with a slower onset occurring in the adult. The aetiology is not fully 
understood but is considered to be a combination of genetic predisposition and 
environmental factors.  
Type 2 diabetes                 
(previously non-insulin 
dependent ot adult-onset 
diabetes) 
Comprises 90-95% hence the vast majority of all diabetes patients and develops 
gradually often at middle age. Characterised by insulin resistance together with a 
relative deficiency in insulin secretion and do not require insulin to survive. Factors 
of importance are co-existent abdominal obesity, hypertension, hyperlipidaemia, 
physical inactivity, smoking and genetic predisposition. 
Other specific types Include diabetes resulting from several genetic mutations e.g. maturity onset 
diabetes (MODY), diabetes following pancreatic diseases, infections or drug use.
Gestational diabetes Hyperglycaemia first recognised during pregnancy and that resolves after delivery. 
Gestational diabetes is present in approximately 2% of all pregnant women in 
Sweden. There is an increased risk for both the foetus and the mother during and 
the immediate time around pregnancy and these women are at increased risk of 
developing type 2 diabetes later in life.
          Diabetes Mellitus and Heart Failure
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Pathophysiology
Diabetes is a complex metabolic disorder caused by a combination of impaired insulin 
signalling and insulin resistance in the liver and the skeletal muscles resulting in decreased 
glucose uptake in peripheral tissues, mainly the liver and the muscles, and increased hepatic 
glucose production (schematically summarised in Figure 2). The combined effect of these 
factors deranges the glycaemic control inducing a chronic state of hyperglycaemia. In 
compensation, the pancreatic β-cells initially increase their insulin production thus giving 
rise to a hyperinsulinaemic state in order to maintain normoglycaemia, this ‘pancreatic 
reserve’ is progressively exhausted leading to manifest diabetes as a result of insufficient 
insulin production.6,21 During the gradual deterioration of glucose regulation, patients may 
have Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) as outlined in 
Table 1. It is believed that patients with impaired glucose tolerance already have an up to 
80% loss of their β-cell function.22 
Treatment
Insulin is the mandatory and life-saving therapy for patients with type 1 diabetes. For patients 
with diabetes (type 2), lifestyle advice, focusing on no smoking, weight loss or at least 
stabilisation and, probably even more important, increased physical activity, is the base upon 
which glucose lowering oral agents or insulin may be added.7,9 Modern glucose lowering 
therapy does mainly belong to one of the following three groups i) insulin providers (insulin, 
sulphonylureas, metglinides, GLP-1 receptor agonists, DPP-4 inhibitors), ii) insulin sensitizers 
(metformin, peroxisome proliferator-activator receptor (PPAR) agonists) and iii) glucose 
Figure 2. Schematic diagram of diabetes pathophysiology. Reproduced from Zaccardi et 
al.6  with permisssion from BMJ Publishing Group Ltd.
α / β cells mass-function Liver and Muscle
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reabsorption inhibitors (SGLT-2 inhibitors).23 There is still a debate on the optimal target 
for glucose control. Presently a HbA1c <53 mmol/mol (<7.0% DCCT) is recommended but 
individualisation is advocated in relation to age, potential comorbidities and vulnerability.8,9,23 
Importantly, diabetes requires a multifactorial management taking concomitantly occurring 
cardiovascular risk factors among them hyperlipidaemia and hypertension into account. The 
treatment should be target driven and lipid- and blood pressure targets are, according to 
international guidelines, more stringent for patients with than those without diabetes.23  
Heart Failure
History
The platform for the future understanding of the role of the heart was established in 1628 when 
Harvey in his Excercatio anatomica de motu cordis et sanguinis in animalibus published the 
first modern view of the circulatory system. He demonstrated that the heart pumped blood via 
arteries, to the tissues and back through veins. This contrasted the ancient view of Galen and 
revolutionized the scientific field (Figure 3).24 
Interest in abnormal heart structure in the form of ventricular dilatation and concentric 
Figure 3. Two views of the circulation A) Galen’s view and B) Harvey’s view. (By permission from 
Katz et al.24 as adopted from Major RH, A History of Medicine. Springfield; III: CC Thomas; 1954: 
and from Starling EH, Principles of Human Physiology, Philadelphia, Pa: Lea & Febiger; 1926.)
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hypertrophy was much in focus during the 18th century. Dilatation was considered to weaken 
the contractile power as stated by Bertin in 1833. About 60 years later Osler postulated 
that while initially adaptive, concentric hypertrophy by time may become maladaptive and 
compromise the prognosis.24 The discovery that X-rays could visualize the interior of the 
body by Röntgen in 1895 enhanced the understanding of cardiac enlargement and pulmonary 
fluid accumulation associated with heart failure. Starling’s demonstration in 1918 that the 
contracting power of the myocardium is enhanced by an increased end-diastolic volume, as 
described in his ‘Law of the heart’,25 paved the way for understanding normal circulatory 
physiology. Cardiac catheterization, described by Forssman and further developed by 
Cournand and Richards, provided insights in the disturbed haemodynamic caused by 
myocardial contractile deficiency causing a reduction in cardiac output and increased filling 
pressures.24 Non-invasive studies of myocardial performance became possible when Edler 
and Hertz in 1954 introduced echocardiography.26 Myocardial biology started to attract 
interest in the 50:s when for example, Olson stated that ‘the problem underlying heart failure 
is impaired energy consumption by the contractile machinery’ suggesting that failing hearts 
are energy starved.27 Theories of reduced myocardial contractility as a contributor to heart 
failure developed in the 1960s.24 A major advance in the understanding of the pathophysiology 
behind heart failure came in 1983 when Harris provided clear evidence that, as a response to 
a too low cardiac output neurohormonal activation caused vasoconstriction, salt and water 
retention and adrenergic stimulation as an initially physiologic but subsequently deleterious 
adaptation.28
The treatment for heart failure was for centuries restricted to drugs that increased the power 
of the failing heart. Ancient Romans, Egyptians, Syrians and Greeks used cardiac glycosides 
including sea onion (Scilla maritima). The beneficial effects of Digitalis were first described 
by Withering in 1785. Attempts to tackle the fluid retention that characterised heart failure was 
originally performed by means of bloodletting and leaches and later on by Southey’s tubes 
that, when inserted into the oedematous legs, drained the excessive fluid accumulation.29 
Even in the 1920s, physicians witnessed that ‘little could be done for most cardiac patients 
except to try to determine what was wrong, after which the treating physicians would wait 
until the patient died to see who was correct’.24 In the 20th century, diuretics were introduced 
and offered symptom relief. A major breakthrough came in the 1980- and 1990s with the 
understanding that targeting the untoward neurohormonal activation by means of angiotensin 
converting enzyme inhibitors (ACEi) and beta-blockers offered not only symptomatic relief 
but also prolonged life.                           
Definition and classification of heart failure 
The 2016 European management guidelines defines heart failure as a clinical syndrome 
characterized by a combination of symptoms and typical signs of myocardial dysfunction 
caused by structural and/or functional abnormalities impairing the ability of the heart to 
receive and/or eject appropriate amounts of blood at rest or during stress (Table 3).30 Cardinal 
symptoms are breathlessness, fatigue and peripheral oedema. They form the basis of the 
diagnosis if combined with objective signs of myocardial engagement, most commonly 
investigated by means of echocardiography supplemented by increased concentrations of 
natriuretic peptides and their precursors (NT-proBNP; BNP) that are secreted in increased 
amounts due to myocardial extension.30
In clinical practice, heart failure has been labeled as due to systolic or diastolic malfunction. 
The former relates to an impaired capacity to eject blood from the left ventricle and the 
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latter to compromised left ventricular filling due to impaired myocardial relaxation. This 
terminology was subsequently abandoned since they were not mutually exclusive.30 The 
current classification is instead based on left ventricular ejection fraction (LVEF). Patients 
with heart failure despite a normal LVEF are considered to have heart failure with preserved 
ejection fraction (HFpEF; LVEF ≥50%). Those with heart failure and a LVEF of 40-49% 
represent a borderline group, which in the most recent European management guidelines has 
been defined as “mid-range” heart failure (HFmrEF) while patients with heart failure and a 
LVEF <40% are labeled as heart failure with reduced ejection fraction (HFrEF). HFrEF is 
the most well defined entity, and the current evidence-based pharmacological therapy, with 
an impact on morbidity and mortality, is restricted to this group.30 
The main clinical classification of the severity of heart failure was presented by the New York 
Heart Association (NYHA) positioning the patients in one of four classes (Table 4).31 A NYHA 
class can be applied in all heart failure patients irrespective of aetiology and level of care.
Epidemiology
Prevalence - The prevalence of heart failure in western adult populations varies between 
1-2%. It increases with advancing age to a prevalence of 10% above 65 years.30,32-34 The 
prevalence is increasing due to an aging population but importantly also due to improved 
survival not the least in ischaemic heart disease.30,35,36 
The proportion of patients with HFpEF varies between 22-73% depending on the LVEF 
Table 3. Definition of heart failure according to the 2016 European Society of Cardiology (ESC). 
Adapted with permission from ESC guidelines 2016.30
HFpEF HFmrEF HFrEF
1. Symptoms ± signs 1. Symptoms ± signs 1. Symptoms ± signs
2. LVEF ≥50% 2. LVEF 40-49% 2. LVEF <40%
3. Elevated levels of natriuretic 
peptides
3. Elevated levels of natriuretic 
peptides
4. Relevant structural heart disease* 
or diastolic dysfunction
4. Relevant structural heart disease* 
or diastolic dysfunction
Symptoms = Dyspnoea at rest or excercise, fatigue, tiredness, ankle swelling  
Signs = Tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral 
oedema, hepatomegaly  
* Left ventricular hypertrophy/left atrium enlargement 
Table 4. New York Heart Association (NYHA) classification of heart failure.
NYHA Class I No limitation in physical activities. Ordinary physical activity does not cause undue fatigue, 
palpitation or dyspnea. 
NYHA Class II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results 
in fatigue, palpitation or dyspnoea.
NYHA Class III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity 
results in fatigue, palpitation, or dyspnoea.
NYHA Class IV Unable to carry on any physical activity without discomfort. Symptoms at rest. If any physical 
activity is undertaken, discomfort is increased.
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cut off and the study population.30,37,38 It is likely that the distribution on HFpEF, HFrEF 
and HFmrEF will change over time with improved treatment and an aging population with 
more comorbidity. As an example data from the Olmstead County show that the proportion 
of HFpEF among patients hospitalized for heart failure increased from 38 to 54% between 
1987 and 2001.39 
Incidence - The annual incidence of heart failure is 5-10/1000 individuals, rapidly increasing 
with age and in general higher in men than women.30,40 In Rotterdam the lifetime risk to 
develop heart failure (after 55 years) was 33% in men and 29% in women and US data are 
similar.41,42 Time trends vary, but it seems as if the increase during the 1980s,43,44 has been 
reverted or at least stabilised during the past decades as illustrated in Figure 4.33,45-48 
Risk factors - The most common etiological entities, accounting for approximately 40% of 
all cases, are hypertension and ischaemic heart disease (IHD). Other contributors are atrial 
fibrillation, valvular heart disease, pulmonary disease and alcohol abuse. Less common 
are myocardial infiltrative, inflammatory and toxic engagements.30 Diabetes, obesity and 
traditional risk factors for IHD are important even for heart failure.15,49 
The different heart failure entities HFpEF, HFmrEF and HFrEF are considered to have a 
somewhat different risk factor profile with increasing age, long-standing hypertension, 
diabetes, atrial fibrillation and female sex commonly seen in HFpEF while IHD, smoking 
and male sex are more prevalent in HFrEF.30 Whether there are specific risk factors that cause 
HFmrEF remains to be elucidated.
 
Prognosis
Mortality among patients with heart failure is high despite the improvement seen with the 
introduction of modern evidence-based treatment as detailed below.45-47,50 Since then age 
adjusted mortality has remained relatively stable with a better survival in women than 
men,33,42,48 and with a similarly compromised long-term prognosis in patients with HFpEF 
and HFrEF.37,38,51
Figure 4. Time trends of age-standardised rates of first hospitalization of heart failure as principal 
diagnosis in (A) men and (B) women in Scotland (Jhund et al.46), Sweden (Barasa et al.45) and West 
Australia (WA; Teng et al.47). The age-standardised rates were based on the standard populations in 
2001 for Scotland and WA and in 2000 for Sweden. Reproduced from Teng et al.47 with permission 
from Wolters Kluwe Heath, Inc.). 
Scotland-Men
Sweden-Men
WA-Men
Scotland-Women
Sweden-Women
WA-Women
H
os
pi
ta
lis
at
io
n 
ra
te
 / 
10
0,
00
0 
po
pu
la
tio
n
H
os
pi
ta
lis
at
io
n 
ra
te
 / 
10
0,
00
0 
po
pu
la
tio
n
1986 1988 1990 1992 1994 1996 1998 2000 2002 20041986 1988 1990 1992 1994 1996 1998 2000 2002 2004
350
300
250
200
150
100
50
0
A
300
250
200
150
100
50
0
B
Isabelle Johansson
18
Pathophysiology
Heart failure develops when the heart is unable to deliver sufficient amounts of blood to meet 
the bodily requirements or has to increase its filling pressures to keep an adequate cardiac 
output. The reasons may be myocyte death and/or dysfunction, myocardial remodelling 
or a combination. To maintain a sufficient cardiac output three adaptive mechanisms will 
be activated, which explains why patients, at least during some time can be relatively 
asymptomatic despite a compromised cardiac function;52 
1) The Starling mechanism by means of which an increased preload, reflected by an el-
evated end-diastolic volume, increases ventricular performance.25 
2) Neurohormonal activation increasing myocardial performance by means of an enhanced 
sympathetic tone and stimulation of the renin-angiotensin-aldosterone system (RAAS) 
in order to maintain arterial pressure and perfusion to vital organs.28 
3) Myocardial remodelling including dilatation of the cardiac chambers and myocardial 
hypertrophy to meet the increased demands induced by the augmented filling pressures. 
The former two represent a more or less immediate response, which during some time may be 
advantageous but, if persistent, will contribute to myocardial remodelling and in the long run to a 
successively deteriorating myocardial function. Thus, as illustrated in Figure 5, neurohormonal 
activation, although initially a physiological response, leads to a negative, vicious cycle,52 
which in addition leads to myocyte loss, collagen deposit and myocardial fibrosis.53
Modern treatment
Symptoms related to congestion have since long been possible to counteract by diuretic agents. 
These should be used on demand i.e. intermittently and with caution since they have several 
adverse effects and may further increase the already enhanced neurohormonal activation. It 
was not until the introduction of neurohormonal deactivation by means of ACE inhibitors after 
the publication of the CONSENSUS and SOLVD trials in 1987 and 1991 respectively,54,55 that 
Figure 5. Neurohormonal activation caused by depressed myocardial function leads to a vicious 
circle further compromising the already reduced myocardial function. 
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both symptoms and longevity could be improved (table 5). Outcome was further enhanced by 
beta-blockers introduced in 1999 after reduction in mortality was demonstrated in the CIBIS-
II, MERIT-HF and COPERNICUS trials.56-58 In 2003, Angiotensin II Receptor Blockers 
(ARB) given to patients intolerant to ACEi was shown to improve outcomes in the CHARM-
Alternative trial,59 and Mineralocorticoid receptor antagonists (MRA) were subsequently 
added in refractory cases following the RALES,60 and EMPHASIS-HF trials.61 Most recently 
the Angiotensin II Receptor blocker Neprilysin Inhibitor (ARNI) was shown superior to the 
ACEi in reducing mortality as demonstrated in PARADIGM-HF trial in 2014.30,62 Besides 
pharmacological treatment, implantable devices may offer symptomatic relief and survival 
benefits in selected cases e.g. Cardiac Resynchronization Therapy (CRT) in patients with 
intra-ventricular conduction defects and Intra Cardiac Defibrillators (ICD) in patients prone 
to develop ventricular tachycardia or fibrillation. For end-stage heart failure, left ventricular 
devices and heart transplantation offer good symptom relief and reduced mortality.30 Last but 
not least physical exercise have beneficial effects in the form of improved physical ability 
and quality of life. The favourable impact of revascularisation in patients with heart failure 
of ischaemic origin is still uncertain.30,64
Diabetes Mellitus and Heart Failure
Epidemiology 
Prevalence - The prevalence of diabetes is considerably higher in patients with cardiovascular 
disease than in the general population. Several studies reported on previously undetected 
diabetes in more than 25% of patients with myocardial infarction and another 40-45% with 
IGT when screened with an oral glucose tolerance test.65,66 Similar proportions were detected 
in patient populations with cerebral and peripheral vascular disease.67 The prevalence of 
diabetes in heart failure populations varies ranging between 13-47%.68 The combination of 
diabetes and heart failure from a general population was investigated in the Reykjavik study 
revealing a diabetes prevalence of 12% in people with compared to 3% in those without heart 
failure. The combination increased by age and is slightly more common among men than 
Table 5. Landmark randomized trials with improved outcome in heart failure with reduced LVEF.
Acronym Drug class Publication year Study name
CONSENSUS ACEi 1987 Cooperative North Scandinavian Enalapril Survival Study54 
SOLVD ACEi 1991 Studies of Left Ventricular Dysfunction55 
CIBIS-II Beta blocker 1999 Cardiac Insufficiency Bisoprolol Study II56 
MERIT-HF Beta blocker 1999 Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure57 
COPERNICUS Beta blocker 2001 Carvedilol Prospective Randomized Cumulative Survival58 
CHARM ARB 2003 Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity59 
RALES MRA 1999 Randomized Aldactone Evaluation Study60 
EMPHASIS-HF MRA 2011 Eplerenone in Mild Patients Hospitalization and Survival Study in heart Failure61 
PARADIGM-HF ARNI 2014 Prospective Comparison of ARNI With ACEi to Determine Impact on Global Mortality in Heart Failure62
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women.32 In an elderly Italian population diabetes was found in 30% of the 10% with heart 
failure.34 Moreover, insulin resistance and undiagnosed glucose abnormalities are common 
in heart failure patients.69,70 Clinical trials in stable heart failure patients usually report a 
prevalence of known diabetes between 20-35%,71-73 approaching 40-45% in decompensated 
heart failure.74 Information on the prevalence of diabetes according to the type of heart failure 
is sparse.75
Conversely, in diabetes populations, several epidemiological studies report on a high 
prevalence, 12-22%, of heart failure.76-78 Moreover there was a high prevalence of unknown 
heart failure (28%), mostly HFpEF, in a recent study of Dutch people above the age of 60 
years.79
Incidence - In the Framingham cohort the incidence of heart failure was twice that among men 
and five times higher in women with than without diabetes during 18 years of follow-up.80 In 
2004, the Kaiser Permanente Northwest study comparing patients with and without diabetes 
identified an incidence of heart failure of 30.9 and 12.4/1000 person years respectively. The 
incidence increased with poor glycaemic control.81 A Swedish study from 2012 on >80 000 
patients with diabetes observed an increased incidence of heart failure with deteriorating 
glucose control ranging from 13.8 to 25.8/1000/person years during seven years.82 
Risk factors – Diabetes and heart failure share many risk factors among them family history, 
age, overweight and a sedentary life-style,30,83,84 and in addition people with diabetes are at 
risk for IHD and hypertension, two of the most important risk factors for heart failure.30 
The concept that there may be a direct relation between diabetes and heart failure dates back 
to 1954 when the Danish Professor Lundbæk published an article on clinically important 
complications in patients with diabetes underlining that heart disease was common and 
suggested the presence of a diabetes specific cardiomyopathy.85 Twenty years later Rubler 
et al.86 published supporting data, although only based on four post-mortem cases. They 
concluded that myocardial disease seemed to be a complication to diabetes in itself and not 
merely caused by coronary artery disease. Shortly thereafter the Framingham study presented 
epidemiological evidence for a strong relation between heart failure and diabetes indicating 
that this association could not solely be explained by traditional risk factors for coronary 
artery disease.80 
Diabetes cardiomyopathy is presently defined as the presence of myocardial dysfunction in 
a patient with diabetes without other obvious causes for cardiomyopathy, such as coronary 
artery disease, hypertension or valvular heart disease.87 Seferovic et al. recently extended 
this by postulating that diabetes cardiomyopathy may give rise to both HFpEF and HFrEF.88 
Prognostic implications of the combination of diabetes and heart failure
There is growing evidence that diabetes and heart failure aggravates the prognosis of each 
other. This has been shown in observational investigations of selected populations 74,89-91 and 
in several randomized heart failure trials,73,92,93 especially in ischaemic heart failure71,91,92,94. For 
example, annual mortality in patients with diabetes has been reported to be as high as 36% 
in patients with heart failure compared with 3% in patients without.95 Another observational 
study of diabetes patients above 65 years found a mortality of 32.7 compared with 3.7 per 
1000 person years during five years of follow-up in patients with and without heart failure 
respectively.78 
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The majority of the studies are restricted to HFrEF populations. Corresponding data investigat-
ing prognostic implications in HFpEF are infrequent but indicate that diabetes predicts mortal-
ity even in this entity.71,96 There is a need for prognostic information from unselected patient 
populations subjected to a contemporary management. 
Pathophysiology in relation to diabetes and heart failure
There are several pathophysiological characteristics considered involved in diabetes 
cardiomyopathy as summarised in Figure 6.
The normal myocardial energy production is generated via β-oxidation of free fatty acids (FFA) 
to about 70% while oxidation of glucose, lactate and other products e.g. ketones contributes 
with about 30%.97 Diabetes already at rest causes a deviation of the energy production away 
from glucose towards β-oxidation of FFA, which in this situation may contribute with 90% of 
the production of energy rich adenosine phosphate (ATP). This pathway is an efficient energy 
provider in states of a sufficient oxygen supply. Glucose oxidation provides more energy 
per mole oxygen, which is an advantage when oxygen supply is limited.98 Multiple factors 
underlie the shift seen in diabetes. Decreased insulin production and sensitivity compromise 
glucose transportation (via GLUT 4) into the myocytes. Insulin deficiency further enhances 
lipolysis inducing an increase of circulating FFA thereby further stimulating myocardial 
utilization of FFA as the predominating energy substrate, a process largely driven by the 
AGEs
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Diabetes cardiomyopathy
Figure 6. Possible mechanism involved in diabetes cardiomyopathy. Adapted from Bugger et al.87  
with permission of Springer. 
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translation factor peroxisome proliferator-activator receptor-α (PPAR-α).99 Unfortunately 
increased β-oxidation of FFA inhibits glucose oxidation via Randle´s cycle,100 contributing 
to diminished cardiac efficiency. The myocardial ability to shift the energy source from FFA 
to glucose is further restricted in stressful situations.97,101 The myocardial lipid overload 
is believed to have toxic effects in itself. This has been referred to as lipotoxicity and is 
characterized by non-oxidative pathways generating toxic lipid intermediates that may 
contribute to mitochondrial dysfunction, oxidative stress, perturbed cellular signalling, 
increased inflammatory activity, necrosis and apoptosis ultimately accelerating the process 
of myocardial fibrosis.87,99 Oxidative stress is also thought to rise as a consequence of 
hyperglycaemia by activated reactive oxygen species (ROS)-driven pathways and of 
processes triggered by protein kinase C (PKC). Increased levels of inflammatory cytokines 
will further enhance insulin resistance.21 
Myocardial contractility is also impaired in diabetes by disturbed Ca2+ handling via decreased 
Ca2+ influx through L-type Ca2+ channels, and by reverse mode Na2+/Ca2+ exchange. 
Furthermore chronic hyperinsulinaemia is involved in impairment of the phosphatidylinositol 
3-kinases (PI3K)/Akt pathway, among others thought to play part in vascular constriction 
and increased apoptosis thereby further promoting left ventricular remodelling.87,99
Another assumption is that Advanced Glycation End products (AGEs) that are more 
common in diabetes, by cross-linking with collagen disturbs the normal degradation of 
collagen inducing accelerated myocardial fibrosis that increases myocardial stiffness and 
compromises relaxation.87 
In summary the major metabolic derangements thus far postulated as explanations for 
diabetes cardiomyopathy are deranged metabolism, reduced myocardial substrate production, 
toxic effects from metabolites, increased oxidative stress, disturbed Ca2+ handling, increased 
myocardial stiffness/fibrosis and reduced coronary flow reserve. 
Treatment
Heart failure treatment in diabetes
For the most part, evidence-based heart failure therapy has a proportionately similar efficacy 
in patients with and without diabetes.23,26 Beta-blockers were initially questioned because of 
their propensity to worsen insulin sensitivity and blunt hypoglycaemic symptoms. There is, 
however, clear evidence that this therapy benefits patients with diabetes and heart failure.103,104 
Likewise RAAS-inhibition has similar effects in patients with and without diabetes. MRAs 
and Renin inhibitors should be used with caution in patients with diabetes due to commonly 
concomitant renal impairment.104 Diuretic agents including thiazides and loop diuretics are 
efficient and usually unavoidable for the relief of symptoms of congestion.23 Whether these 
recommendations are followed in the everyday clinical care is incompletely explored.
Diabetes treatment in heart failure
Glucose lowering in heart failure patients is complicated by the potential side effects of the 
pharmaceutical agents. Whether such phenomena is even part of the explanation for the 
serious prognosis of heart failure when diabetes is present is not known. Insulin sensitizers 
have the propensity to worsen heart failure by inducing fluid retention and some agents 
were because of this withdrawn from the market.105-107 Metformin was for long considered 
          Diabetes Mellitus and Heart Failure
23
contraindicated due to the assumption that the risk for lactic acidosis became increased, 
especially in the presence of impaired renal function. More recent data did not verify this 
and metformin is recommended as first-hand choice in the current European management 
guidelines.23 The benefit of insulin treatment in patients with diabetes and heart failure is 
debated. The main effect of insulin is to decrease blood glucose but it may also increase 
myocardial blood flow, decrease heart rate, increase sodium retention i.e. fluid retention and 
cause a modest increase in cardiac output.108,109 Beneficial effects on myocardial function 
have been reported, but also that insulin may be associated with increased morbidity110 
and mortality.111,112 Concerns have been raised regarding a potentially increased risk of 
heart failure hospitalization seen with the DPP-4 inhibitor saxagliptin113 and additionally a 
tendency even with alogliptin,114 however, not confirmed for sitagliptin.115,116 Promising are 
the findings with the SGLT-2 inhibitor empagliflozin that decreased the need for heart failure 
hospitalisations by 35% in the EMPA-REG OUTCOME study in patients with diabetes and 
established cardiovascular disease,117 which probably was a driving force behind the 13% 
mortality reduction seen with this SGLT-2 inhibitor.118 Two studies with the GLP-1 receptor 
agonists liraglutide and semaglutide (LEADER and SUSTAIN-6) recruiting patients with 
diabetes with established cardiovascular disease or at high cardiovascular risk revealed 
mortality (LEADER) and morbidity benefits (SUSTAIN 6), however, without impact on 
heart failure hospitalization.119,120 
Drugs targeting metabolic modulation e.g. trimetazidine, etoxomir and dichloroacteate that 
shifts myocardial metabolism from β-oxidation of FFA towards glucose utilisation have 
so far not provided great promise even if further exploration is mandated.121-123 A potential 
myocardial metabolic modulating effect by GLP-1 receptor agonists are still under extensive 
investigation. So far the results are conflicting.124,125 Promising emerging modulators are 
ketones and glucagon.101,126 
In summary, major efforts in the management of hyperglycaemia and myocardial metabolism 
have been the subject of research for a long time, although it is only just recently that the 
impact of heart failure development has been successfully intervened with. 
Revascularization 
Regardless of the presence of diabetes revascularization with either percutaneous coronary 
intervention (PCI) or coronary artery bypass graft surgery (CABG) is a cornerstone when 
managing patients with myocardial ischemia.127 According to the FREEDOM trial CABG 
is to be preferred over PCI in patients with diabetes and multivessel or complex vessel 
disease,128 and when PCI is preferred patients with diabetes should be given drug eluting 
stents.128 The STICH trial, including both patients with and without diabetes, addressed the 
prognostic importance of CABG in a randomized trial of patients with LVEF <35% and 
with two- and three-vessel disease. In the intention to treat analyses the STICH investigators 
reported on lower cardiovascular and total mortality in the CABG group.129 However, in the 
viability sub-study of STICH, there was no correlation between myocardial viability and 
benefits with the use of CABG. Although these studies have provided information, there 
is still a lack of studies on the prognostic impact of revascularization in unselected, well-
defined populations of heart failure patients with diabetes.
Isabelle Johansson
24
Sex and gender aspects of diabetes and heart failure
More women than men live with heart failure partly due to their longer life expectancy. In 
addition survival in heart failure is mostly reported as better in women, who tend to develop 
heart failure at older ages, more often with HFpEF and less frequently due to IHD than men.130 
The protective effect against IHD seen in women seems to be attenuated in the presence of 
diabetes.15,131 That women with diabetes have a poor prognosis after myocardial infarction 
and high heart failure prevalence was first described in 1961 by Björck and colleagues.132 
Their findings were confirmed by Kannel et al. in 1974 in the Framingham cohort.80 The 
reason for the increased cardiovascular risk in women with diabetes is not completely 
understood, but there are indications that women with compared with those without diabetes 
are more likely to have multivessel coronary artery disease,133 and it has been suggested that 
they do not get a fully established evidence-based management although previous reports 
regarding this are contradictory.134-139
Prognosis related to sex and gender differences (the former relating to biological and the 
latter to sociocultural aspects), in heart failure patients with diabetes are sparse and somewhat 
contradictory. The Danish Investigators and Arrythmia ON Dofetilide (DIAMOND) reported 
that diabetes negatively impacted survival particularly in women who got less of evidence- 
based treatment,140 while a large meta-analysis including 42 000 patients demonstrated 
that women with diabetes had a slightly better survival than men after adjustments for 
important confounders but much higher mortality compared with women without diabetes.51 
Mechanisms behind these findings remain to be elucidated. 
Rational for registry based analyses
Patient registries have the advantage over randomised clinical trials to offer comprehensive 
patient materials without any inclusion or exclusion restrictions. This is particularly true 
for nationwide, multicentre registries with high quality and validated variables. Such 
registries offer better information on the true prevalence of the actual patient category and 
their everyday management and prognosis than clinical trials with all their restrictions. 
However, to derive appropriate information and draw adequate conclusions from registry-
based analyses, it is mandatory to be aware of the quality and validity of reported variables 
and knowledge on limitations related to non-randomised treatment data. Thus, registry based 
analyses on treatment effects cannot serve as a substitute to randomised trials. They do, 
however, generate hypotheses for future research. 
Swedish National Quality Registries 
Swedish National Quality Registries were originally instituted to enable quality follow-up 
to improve health care. Since the initiation of the first registry in 1975, another 96 have been 
added across all health care production with continuous financial support provided from 
the Swedish state (http://kvalitetsregister.se/englishpages). Swedish registries are unique 
due to the ten-digit personal number of each Swedish citizen, which apart from enabling 
the initiation of well-functioning registries also allows cross-linking the registries with each 
other, leading to increased knowledge about treatment patterns and prognosis. The registries 
have thereby evolved into not only being a provider of information for quality follow-up but 
also bringing valuable source of information for researchers. The validity and quality of the 
registries are determined according to four certification levels (level 1-3 and candidate level, 
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where level 1 equals top certification) issued by the Swedish National Board of Health and 
Welfare.141  Quality is ensured by the requirements to follow specific pre-set goal criteria 
for each certification level. Every quality registry is obliged to have a registry holder and a 
steering group. Whether financial support is provided is annually judged upon the relevance, 
design, competency and follow-up ensuring high quality and appropriate use of common 
financial resources.
Gaps in knowledge 
According to available data the combination of heart failure and diabetes is common and 
ominous. Still there is a lack of knowledge on how this combination is best managed. 
Moreover, further elucidation is needed when it comes to the reasons for the impact of 
diabetes and what risk factors are most important for the compromised survival. Among 
them are the influence of sex, heart failure aetiology and heart failure type. Large, registry 
based analyses comparing heart failure patients with and without diabetes may provide 
valuable information, in particular if derived from unselected contemporary populations. In 
this context, the Swedish Registry on Heart Failure (SwedeHF) offers a unique opportunity 
to analyse the nature of heart failure in patients with diabetes in a population collected from 
all day practices across Swedish hospitals and outpatient clinics. The real proportion of such 
patients, and insight into the actual long-term prognoses and management can be analysed. 
With such expanded knowledge, it should be possible to give useful advice for improving the 
outlook for this patient category.
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AIMS
The overall aim is to study patients with diabetes and heart failure in order to provide a 
deeper understanding of underlying reasons for their poor prognosis and to identify possible 
roads to improvement. 
Specific aims are to analyse
I. the risk factor panorama and treatment pattern in heart failure patients comparing 
patients with and without diabetes and to investigate the association between diabetes 
and long-term prognosis. (Study I)
II. whether risk factor pattern, use of evidence-based heart failure therapy and long-term 
survival differs between women and men in heart failure patients with and without 
diabetes. (Study II)
III. the proportions and prognostic impact of ischaemic and non-ischaemic heart failure 
and to investigate the role of previous revascularization in patients with and without 
diabetes. (Study III)
IV. the prevalence, demographic characteristics and prognostic implications of diabetes 
in patients with preserved (HFpEF), mid-range (HFmrEF) and reduced (HFrEF) heart 
failure. (Study IV) 
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PATIENTS AND METHODS
Patients
The four studies behind this thesis are based on a study population extracted from the Swed-
ish Heart Failure Registry, SwedeHF, slightly adapted for the individual study purposes as 
detailed in Table 6.
Table 6. Summary of the four studies behind this thesis.
Study I Study II Study III Study IV
Aim DM vs. No DM, 
characteristics and 
prognosis
DM, differences in 
women and men
DM and ischaemic vs. 
non-ischaemic HF.
Role of 
revascularization
DM in different types 
of HF; HFpEF, 
HFmrEF and HFrEF 
Data source SwedeHF
Study design Prospective observational registry study
Source population Specialist HF care             
Inclusion criteria Clinician judged HF, 
known DM status
Clinician judged HF, 
known DM status 
and sex
Clinician judged HF, 
known DM and 
IHD status
Clinician judged 
HF, known DM and 
LVEF status
Inclusion years 2003-2011
End of follow-up 30th Sept 2011 30th Sept 2011 30th Sept 2011 31st Dec 2014
Outcome All-cause mortality
Number of patients 36 274                             36 274                          35 163 30 696                                
Sub group 
distribution
- 39% W /  61% M 51% IHD / 
49% no IHD 
22% HFpEF / 
21% HFmrEF / 
57% HFrEF
Proportion with 
diabetes
24% Women: 23%                      
Men: 25%
IHD: 30%                 
No IHD: 19%
HFpEF: 25% 
HFmrEF: 24%
  HFrEF: 24%
Adjustments Baseline characteristcs, risk factors and treatment
Staistical analysis Descriptive statistics 
and hypothesis 
testing, survival by 
Kaplan Meier and 
Logistic regression. 
Descriptive statistics 
and hypothesis 
testing, survival by 
Kaplan Meier and 
logistic regression. 
Age-matched 
analyses. 
Descriptive statistics 
and hypothesis 
testing, survival by 
Kaplan Meier and 
Cox proportional 
hazard regression. 
Propensity score 
analysis.
Descriptive statistics 
and hypothesis 
testing, survival by 
Kaplan Meier and 
Cox proportional 
hazard regression.
Abbreviations: DM, Type 2 diabetes; HF: Heart Failure; HFmrEF, Heart failure mid range Ejection Fraction; HFpEF, Heart failure 
preserved Ejection Fraction; HFrEF, Heart failure reduced Ejection Fraction; Specialist HF care, Hospital ward (internal medicine or 
cardiology) or specialist out patient clinic; M, Men; SwedeHF, The Swedish Heart Failure Registry; W, Women
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Definitions 
Most variables were defined as outlined in SwedeHF and the most pertinent of them are 
listed below. For a full description see Appendix 1. 
Heart failure - Diagnosed by the attending physician based on guideline recommendations at 
the time of inclusion (current definition, Table 3).
Type 1 and 2 diabetes – The physician in charge reported history of diabetes stratified 
according to type 1, or type 2 reported by glucose lowering regime (life-style advice only, 
oral glucose lowering drugs and/or insulin). For the studies comprised in this thesis type 2 
diabetes was reclassified yes or no. All patients with type 1 diabetes were excluded from the 
thesis.  
IHD defined as present, whether verified or not by coronary angiography, or absent based on 
the case history from patient records. An adapted definition was used for IHD in Studies III-
IV where patients reported as without IHD but with a confirmed coronary revascularization 
procedure or history of previous myocardial infarction were reclassified as having IHD. 
Revascularization – Reported by the physician in charge as a history of coronary artery 
bypass surgery (CABG) and/or percutaneous coronary intervention (PCI). 
LVEF - The most recently estimated EF reported stratified into four different classes: LVEF 
≥50%, 40-49%, 30-39% and <30%. An estimated EF was not obligatory for inclusion in the 
SwedeHF and it was not possible to report by which method the LVEF had been estimated.
NYHA class – Defined according to the New York Heart Association classification of 
symptom severity (Table 4).31
Renal function - Based on serum creatinine, the Estimated Glomerular Filtration Rate 
(eGFR) was estimated according to the Cockroft-Gault formula (Studies I-II)142 or by the 
MDRD formula (Studies III-IV)143. It was expressed as a continuous variable as well as 
categorized into four groups: >90, 60-89, 30-59 and <30 ml/min or ml/min/1.73m2 
Chronic Kidney Disease (CKD) – Based on the evaluated eGFR, CKD was considered 
present at clearance <60 mL/min in Studies I-II and <60 mL/min/1.73m2 in Study III-IV. 
Laboratory measurements
Measurements of NT-proBNP, Hb, creatinine, blood lipids, random plasma glucose and 
glycosylated haemoglobin A1c (HbA1c) were accepted as analysed by the local hospital 
laboratories.
Source of data
The Swedish Heart Failure Registry (SwedeHF) 
The Swedish Heart Failure Registry (abbreviated SwedeHF throughout the thesis but until 
March 2015 referred to as S-HFR) is a National Quality Registry holding patients with 
clinician-judged heart failure. The registry was initiated in 2003 by Professor Ulf Dahlström, 
Linköping and Associate Professor Magnus Edner, Stockholm. The registry was created to 
provide quality follow-up of heart failure diagnosis and treatment in Sweden and to identify 
areas in need of further efforts to reach an optimal and equal heart failure evidence-based 
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management according to actual guidelines all over Sweden.144 An additional objective was 
to provide comprehensive information for epidemiologic research on heart failure patients 
as reflected by contemporary all day practice. The registry is supported by the Swedish 
National Board of Health and Welfare and is independent of commercial interests. A detailed 
description is available,145 and the protocol, registration forms and annual reports can be 
found at http://www.swedehf.se. 
Data collection and follow-up
SwedeHF is an online-based registry comprising >70 pre-selected variables related to risk 
factors, treatment and indicators of myocardial function. During the time period covered 
by the present thesis (2003-2011) variables were reported at the time for hospital discharge 
or after an out patient visit via an internet-based case report form to a central database at 
Uppsala Clinical Research Center (UCR). The database is run monthly against the Swedish 
population registry by use of the unique ten-digit personal number of each Swedish citizen, 
thereby providing information necessary for analyses of all-cause mortality. This information 
is therefore complete without any loss of follow-up.  
Quality indicators
Coverage - SwedeHF has since the start steadily increased in coverage from 14 including 
centres reporting 861 patients in 2003 to 65 centres and 47 000 unique patients in 2011, 
when 83% of all hospitals in Sweden and 10% of the primary care centres were connected. 
The time period covered in Studies I-IV starts in January 2003 and lasts until the end of 
September 2011. In the annual SwedeHF report from that year it is reported that the registry 
had an estimated coverage of 82%,146 and had reached the certification level 3 issued by the 
Swedish National Board of Health and Welfare.140 
Coverage estimates may, however, be uncertain and complicated mainly by two reasons: 
1) heart failure is a clinical syndrome without a distinct starting point; 2) there is some 
uncertainty on how to report the International Classification of Diseases (ICD) codes for 
heart failure since there may be varying position as a 1st or 2nd diagnosis during a hospital 
stay. For 2011 two different methods were applied to evaluate the coverage. The results 
differed significantly from 82% coverage based on hospitalisation data from the Swedish 
Epidemiological Centre to 37% in a more recent estimate when using data on hospitalization 
provided by the Swedish Board of Health and Welfare and that in contrast to the former also 
required echocardiographically verified heart failure.147 
Reported and missing variables - Examples of variables reported in 100% are age, sex, 
creatinine, and haemoglobin. The majority of other, clinically important variables on baseline 
characteristics and treatment have a reported frequency >95%. Echocardiography was 
registered in 87% of the patients, NYHA class was available in 69%. NT-proBNP was not 
mandatory before 2011 and is only available in about 26%. HbA1c was reported in 6% and 
random plasma glucose in about 28%.
Variables registered in SwedeHF had not been validated at the time of the present data 
extraction. Continuous quality monitoring started in 2012 and has so far reported a varying 
quality of the registered data between the different reporting centres. Low consistency between 
reported information to SwedeHF and the original patient record is mainly seen for NYHA-
classes, alcohol consumption and smoking.146 It can be assumed that these observations may 
be relevant even before 2012.
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Study populations and design
The original study population comprise all patients from hospital-based (68%) and specialised 
outpatient heart failure clinics (32%) registered in SwedeHF January 1, 2003 to September 
30, 2011. The patient selection in Studies I-IV is presented in Figure 7.
Specific study aims, population and design
Study I
To test the hypothesis that risk factor pattern, treatment and prognosis differ between patients 
with and without diabetes in a contemporary heart failure population collected from an everyday 
health care setting.
The original study population was analysed comparing patients with and without diabetes. The 
impact of diabetes was further studied in sub-groups of different age groups: ≤65 years, 66-80 
and >80 years. Follow-up for all-cause mortality lasted until September 30, 2011.
Study II
To test the hypothesis that sex and gender influences risk factor pattern, prescribed treatment 
and the vital prognosis in heart failure patients in the presence of diabetes to the disadvantage 
of women with diabetes.
The original study population was used and analysed stratified by sex, diabetes and age 
groups; ≤65 years, 66-80 and >80 years. To further circumvent age bias, three sub-cohorts 
of age-matched populations were constructed (±1 year) and compared: (1) men and women 
with diabetes; 2) women by diabetes status; 3) men by diabetes status. Follow-up for all-cause 
mortality lasted until September 30, 2011.
Study III
To test the hypothesis that ischaemic heart failure is common in patients with diabetes and 
negatively impacts prognosis. Further to investigate previous revascularization pattern and analyse 
whether the role of previous revascularization differs in patients with and without diabetes.
Study 
cohort
36 274
Women
14 297
39%
Men
21 977
61%
No DM
16 459
75%
DM
5518
25%
No DM
11 006
77%
DM
3291
23%
Original 
dataset
64 140
Original 
study 
population
36 274
Study 
cohort
36 274
DM
27 465
25%
No DM
8809
75%
1111 IHD 
unknown
Study 
cohort
35 163
IHD
17 891
51%
No IHD
17 272
49%
No DM
14 029
81%
DM
3243
19%
No DM
12 574
70%
DM
5317
30%
5578 LVEF 
unknown
Study 
cohort
30 696
HFmrEF
6483
21%
HFpEF
6705
22%
No DM
5047
75%
DM
1658
25%
No DM
4921
76%
DM
1562
24%
HFrEF
17 509
57%
No DM
13 241
76%
DM
4267
24%
27 866 Excluded: 
22 349 Repeat registrations
269 Patients included 2000-2002
16 No mortality follow-up (included after 110930)
169 Erroneous registration 
14 age ≤0 years
137 survival <0 days
2 no gender
4 551 Primary care patients
359 Missing data on glucometabolic category
169 Type 1 diabetes
Study I Study IIIStudy II Study IV
Figure 7. Schematic patient selection in Studies I-IV.
          Diabetes Mellitus and Heart Failure
31
All patients with available information on the presence or absence of IHD were selected. 
Baseline and prospective survival analyses were performed stratified by diabetes and IHD 
and further in patients with IHD according to diabetes status and history of revascularization. 
Follow-up for all-cause mortality lasted until September 30, 2011.
Study IV
To test the hypothesis that diabetes is more common in HFpEF than in the other two entities and 
that the prognostic implication is similar in all types of heart failure.
All patients from the original study population with reported information on LVEF were 
selected and analysed according to heart failure entity; HFpEF, HFmrEF and HFrEF and further 
stratified by diabetes. Follow-up for all-cause mortality lasted until December 31, 2014.
Statistical analyses
All analyses in the PhD-project were undertaken by use of SAS statistical software, version 
9.3 (Studies I-II) and version 9.4 (Studies III-IV). A 5% level of significance with a two 
sided p-value of <0.05 was considered statistically significant.
Descriptive statistics and hypothesis testing 
Studies I-IV - Differences in continuous variables between independent groups were tested 
for statistical significance by use of Student’s t-test or when more than two independent 
groups by ANOVA-test and Kruskal-Wallis significance test. Natriuretic peptides were 
logarithmically transformed prior to t-test. Quantitative, normally distributed variables are 
presented as the mean (SD) and 95% confidence intervals (CI) or, when appropriate median 
and range. Categorical variables were compared testing the hypotheses of variables in 
contingency tables through chi-square test and are presented as counts and proportions (%). 
In analysing laboratory variables, impossible values were excluded from analysis. 
Survival analyses
Four per cent survived less than 30 days after inclusion in SwedeHF and in order to avoid 
bias on its effect between patients with and without diabetes, analyses were also performed 
excluding those. This did not change overall baseline characteristic and prognostic differences 
in the comparison of patients with and without diabetes, therefore all the all patients were 
kept in the analysis. As a general rule, variables included in the multivariate adjustment 
models were those with less than 5% reported missing values and a univariate p-value <0.05 
and include baseline characteristics, patient history and on-going treatment or else, when 
covariates where considered clinically important with the potential of altering the outcome, 
such were included as detailed in Table 7.
Differences in all-cause mortality between the groups were analysed by log-rank test and 
illustrated through Kaplan-Meier curves in Studies I-III and further by age-adjusted survival 
curves in Studies III-IV by use of Cox regression analysis. Uni-, and multivariate logistic 
regression models were used to detect predictors of mortality in Studies I-II while Cox 
proportional hazard regression was applied in Studies III-IV. A formal test of interaction 
between mortality, sex and diabetes was performed in Study II by use of logistic regression. 
In Study IV, interaction was tested between mortality, LVEF and diabetes by use of Cox 
proportional hazard regression. A sensitivity analysis was performed in Study IV excluding 
those with pervious valvular heart disease. 
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Matched analyses (age and sex)
Study II: Three age-matched (±1 year) sub-cohorts were constructed (detailed in Figure 
1, Study II): 1) men and women with diabetes (n=6452; mean age 76.2 vs. 77.1 years); 2) 
women by diabetes status (n=6582; mean age 77.5 vs. 76.5 in those with and without diabetes 
respectively); 3) men by diabetes status (n=11036; 72.6 vs. 71.6 in those with and without 
diabetes).
Evaluation of coronary intervention by propensity score analysis 
Study III: Due to the observational character of the investigation, a propensity score model 
was applied to avoid potential bias regarding the impact of previous revascularization on all-
cause mortality. The propensity score, expressing the probability of an assigned treatment, in 
this case revascularization, given a set of known baseline characteristics was used to balance 
the study population in regard to a chosen dependent variable.148 Logistic regression was used 
to estimate individual propensity scores for the history of revascularization in patients with 
IHD and diabetes (n=5182) with a good fit (Hosmer and Lemeshow-test; p=0.27 [p>0.05 
is considered a good fit] and c-statistic of 0.7) based on 26 baseline variables (including 
demographics, medical history and reported pharmacological treatment).148 The selected 
variables were those that affected all-cause mortality in univariate logistic regression 
given they had a reasonably low amount of missing data. An individual propensity score 
was estimated for 3467 patients with complete information of all variables. The impact of 
previous revascularization on all-cause mortality was thereafter determined by means of Cox 
regression adjusted for the propensity score. 
Table 7. Summary of multiple covariate adjustments in Studies I-IV.
Study I Main model: Diabetes, age, gender, HF duration, blood pressure, IHD, 
hypertension, atrial fibrillation, pulmonary disease, revascularization, valvular 
surgery, eGFR class, Hb class, weight, ACEi, ARBs, beta-blockers, MRAs, 
diuretics, digitalis, nitrates,  antithrombotic agents.                         
Additional model: LVEF added
Study II Total cohort: Diabetes, age, gender, level of care, blood pressure, HF duration, 
LVEF, blood pressure, IHD, hypertension, atrial fibrillation, pulmonary disease, 
revascularisation, valvular surgery, eGFR class, haemoglobin class, weight, 
ACEi, ARBs, beta-blockers, MRAs, diuretics, digitalis, nitrates, statins and 
antithrombotic agents                                         
Matched groups: Above model minus diabetes or gender in their specific groups 
Study III Model 1: Diabetes, age, gender, level of care, HF duration, weight, blood pressure, 
LVEF-class, eGFR-class, Hb-class, hypertension, atrial fibrillation, pulmonary 
disease, ACEi, ARB, beta-blockers, MRAs, diuretics, digitalis, nitrates, statins, 
antithrombotic agents                                            
Model 2: NYHA class and heart rate added to Model 1
Study IV Model 1: Diabetes, age, gender, level of care, HF duration, weight, blood 
pressure, Hb class, eGFR class, IHD, hypertension, atrial fibrillation, pulmonary 
disease, valvular heart disease, revascularization, ACEi, ARB, MRA, beta-
blockers, diuretics, statins, nitrates, Aspirin, anticoagulants
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Ethical considerations
Establishment of the SwedeHF and registration and analysis of data were approved by 
the Swedish National Review Board of Health and Welfare, the Swedish Data Protection 
Authority and the Ethical Review Board at Linköping University. SwedeHF in itself and 
Studies I-IV agree with the Declaration of Helsinki. Individual patient consent is not required 
or obtained, but patients are informed of being entered into the registry and are allowed to opt 
out (Dnr 2011/1922-31/3 and M196-09).
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RESULTS
Selected patient characteristics for Studies I-IV are presented in the Table 8. 
Table 8. Selected patient characteristics in Studies I-IV. P-value <0.0001 unless otherwise stated.
STUDY I STUDY II
No DM                                  DM
No DM          DM Men Women  Men      Women 
Number of patients  27 465 8809 16 459 11 006 5518 3291
 Proportions 75% 25% 60% 40% 63% 37%
VARIABLES
Demographics
Age, mean ± SD, years 75±13 74±11 73±13 79±12 73±11 78±10
Age-group (%)
       ≤65 21 20 26 14 25 12
       66-80 38 49 41 33 51 45
       >80 41 31 33 53 24 43
Male sex (%) 60 63 100 . 100 .
Level of care (%), Hospital/O.P. 66/34 73/27 62/38 74/27 69/31 81/19
Weight, mean ± SD, kg 76±18 84±19 81±16 67±16 89±18 76±18
Duration of HF (%; ≥6 months) 47 56  47† 46† 57† 56†
NYHA (%), III & IV 42 51 40 22 50 51
CKD-MDRD (%) 50 59 44 58 54 68
CKD-CG (%) 56 53 47 69 46 66
Disease history (%)
Ischemic heart disease 45 59 49 40 62 54
Hypertension 43 60 40 48 58 63
Atrial fibrillation 49 45 49† 50† 45† 45†
Pulmonary disease 17 19 17 18 17 18
Valvular heart disease 22 18 20 24 17 20
iDCM 12 9 15 8 11 6
Previous intervention (%)
Revascularisation 22 32 28 13 38 23
Valvular surgery 5† 5† 6 5 6 4
Biochemical
Hb-class (% anaemia) 34 45 36 31 46 42
NT-proBNP (pg/ml; median)‡ 2860† 2870† 2673 3112 2736 3208
Left ventricular function (%)
LVEF ≥50% 22† 22† 15 32 16 33
LVEF 40-49% 21† 21† 20 23 20 23
LVEF 30-39 27† 27† 20 24 29 23
LVEF <30% 30† 30† 35 21 35 21
†Not significant, ‡ Logarithimically transformed prior to t-test.
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Table 8. Selected patient characteristics in Studies I-IV, continued.
STUDY III STUDY IV
No IHD                 IHD HFpEF HFmrEF HFrEF 
No DM DM No DM DM No DM DM      No DM DM   No DM DM
Number of patients 14 029 3243 12 574 5317 5047 1658 4921 1562 13 241 4267
 Proportions 81% 19% 70% 30% 75% 25% 76% 24% 76% 24%
VARIABLES
Demographics
Age, mean ± SD, years 73±14† 74±11† 77±11 75±10 78±11 76±9 75±12† 74±10† 72±13† 72±11†
 Age-group (%)
       ≤65 27 23 15 17 13 15 22 20 29 25
       66-80 35 45 41 52 36 50 41 52 42 51
       >80 38 31 44 31 50 35 37 28 29 24
Male sex (%) 56† 57† 65† 66† 44 47 60 61 71 73
Level of care (%), Hospital/O.P. 65/32 73/27 68/32 74/26 75/25 83/17 60/40 70/30 59/41 67/33
Weight, mean ± SD, kg 76±19 86±21 75±16 83±18 74±18 86±20 77±18 85±20 77±17 84±18
Duration of HF (%; ≥6 months) 41 49 54 61 48 53 46 55 45 58
NYHA (%), III & IV  38  47  46  54 39 44 31 40 45 57
CKD-MDRD (%) 45 55 56 62 55 63 48 58 46 57
CKD-CG (%) 50 48 62 57 63 55 51† 50† 49† 50†
Disease history (%)
Ischemic heart disease . . . . 38 49 51 66 50 68
Hypertension 41 60 45 59 52 68 45 63 38 55
Atrial fibrillation 55 51 43 40 57 50 51 48 44 40
Pulmonary disease 17 20 18 18 21 25 17 20 16† 17†
Valvular heart disease 22 18 21 18 30 21 22 18 22 19
iDCM 16 12 7† 7† 3 2 6 4 20 15
Previous intervention (%)
Revascularisation . . 48 53 16 24 27 36 25 38
Valvular surgery 5 14 6† 6† 7 6 6† 7† 5† 4†
Biochemical
Hb-class (% anaemia) 30 41 40 47 41 49 33 46 30 41
NT-pro-BNP (pg/ml; median)‡ 2625† 2610† 3203† 3121† 2275† 1835† 2227 2658 3147 3628
Left ventricular function (%)
LVEF ≥50% 26 31 18† 17† 100 100 . . . .
LVEF 40-49% 20 19 23† 22† . . 100 100 . .
LVEF 30-39 24 21 31† 31† . . . . 48 48
LVEF <30% 30 29 29† 31† . . . . 52 52
†Not significant, ‡ Logarithimically transformed prior to t-test.
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Study I
Characteristics of diabetes vs. no diabetes in the total cohort
Of 36 274 patients, 8 809 (25%) had diabetes. The patients with diabetes were somewhat 
younger (mean age 74 vs. 75 years), more often of male sex, had longer heart failure 
duration and were more often in NYHA class III-IV while LVEF was similar in the two 
groups. As detailed in Table 8, patients with diabetes had more comorbidities, particularly 
hypertension (60 vs. 43%) and IHD (59 vs. 45%). Of the latter, 32% of patients with and 22% 
of those without diabetes respectively had been revascularized. Renal function did not differ 
substantially between patients with and without diabetes. When evaluated by the Cockroft-
Gault formula the proportion with CKD was 53 and 56% and according to the MDRD 
estimation 59 and 50% respectively. Pharmacological treatment was more extensive in those 
with diabetes and, in general ACEi/ARBs and RAAS- and beta-blockade was frequently used 
and MRAs were less commonly prescribed. Use of device treatment was limited (<3% of the 
total population received cardiac resynchronisation). 
Mortality
The median follow-up time was 1.9 years (range 0 to 8.7). Survival was significantly 
lower in those with compared with those without diabetes (log-rank p<0.0001). One-year 
mortality was 23% in patients with and 19% in those without diabetes and the corresponding 
proportions after five years were 59% and 52% respectively. The mortality difference was 
most apparent in patients below the age of 65 years (Figure 8 a-c) and in that group diabetes 
was associated with a 60% higher adjusted mortality risk (OR 1.61; 95% CI 1.31-1.92, 
p<0001). The increased mortality among patients with diabetes was evident across all age 
groups. Important independent predictors of mortality among patients with diabetes were an 
eGFR <30 ml (OR 4.43; 95% CI 3.41-5.75, p<0.0001), the presence of IHD (OR 1.68; 95% 
CI 1.47-1.94), a LVEF <30% (OR 1.73; 95% CI 1.46-2.07, p<0.0001) and the presence of 
pulmonary disease (OR 1.45; 95% CI 1.25-1.68, p<0.0001).
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Figure 8. Kaplan Meier curves of survival by diabetes (DM) status and age group, in panel A) patients 
≤65 years, panel B) patients 66-80 years and panel C) patients >80 years of age. Log-rank p<0.0001 
in all comparisons.
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Study II
Comparison of sex differences in the total cohort 
Thirty-nine per cent of the 36 274 patients were women and they were in general older than 
men (Table 8). The prevalence of diabetes was similar among women and men (23 vs. 25%). 
Figure 9 presents the comorbidity pattern. Women were, regardless of their diabetes status, 
less likely to receive evidence-based heart failure treatment such as RAAS-inhibition and 
beta-blockers while they were more frequently prescribed diuretics (Figure 10) and in case of 
IHD, women less often had a history of revascularization compared with men. 
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Comparison of men and women with diabetes
Women with diabetes were older than their male counterparts (78 vs. 73 years). They did more 
frequently have hypertension, CKD (66% vs. 46%) and HFpEF (LVEF ≥50%; 33 vs. 16%) while 
IHD was more common in men apart from in the age-group ≤65 years where the proportions 
with IHD and hypertension were similar (49 vs. 52% and 58 vs. 57% respectively) as was the 
severity of heart failure symptoms expressed as NYHA class (class III-IV 50% vs. 51%).
Comparison of women with and without diabetes
Women with and without diabetes were of similar age (79 vs. 78 years). Patients with diabetes 
were heavier, had a longer duration of heart failure, were more frequently in NYHA classes 
III-IV (51 vs. 43%) and had a slightly higher median NT-pro-BNP (3208 vs. 3112 pg/ml) 
while renal function was similar. Further, IHD and hypertension were more frequent among 
women with diabetes particularly in the age-group ≤65 years where these comorbid diseases 
were twice as common in the presence of diabetes.
Comparison of men with and without diabetes
The mean age in men with and without diabetes was similar (73 years). Men with diabetes 
were heavier, had a longer duration of heart failure and were more often in NYHA classes 
III-IV (50 vs. 40%). Irrespective of age IHD and hypertension were more frequent in patients 
with diabetes while LVEF, eGFR and NT-pro-BNP was uninfluenced of the diabetes state. 
Mortality
The median follow-up time was 1.9 years (range 0-8.7). Survival was significantly lower in 
patients with diabetes regardless of sex (Figure 11 a-c). The age-matched cohorts reveal that, 
within the diabetes group, there was no survival difference between men and women (log-
rank p=0.18; Figure 11a).  In contrast women without diabetes had a better prognosis than 
their male counterparts (log-rank p<0.0001). Women with diabetes had reduced longevity 
compared with those without (Figure 11b) and a similar pattern, albeit somewhat less 
apparent, was seen in men (Figure 11c). The Forest plot in Figure 12 presents unadjusted and 
adjusted associations of sex, diabetes and mortality. In the diabetes population, female sex 
did not remain as an independent predictor of mortality after extensive covariate adjustment, 
not among all patients with diabetes and heart failure (OR 0.90; 95% CI 0.79-1.03; p=0.14) 
nor in the age-matched diabetes group (OR 0.92; 95% CI 0.79-1.06; p=0.25). 
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Figure 11. Survival by sex in A) the age-matched diabetes (DM) cohort, B) survival in women (W) 
by DM in the matched female sub-cohort and C) survival in men (M) by DM in in the age-matched 
male sub-cohort.
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Among the women, diabetes was an independent predictor of mortality (adjusted OR 1.72; 
95% CI 1.53-1.94; p<0.0001 in the total and OR 1.64; 95% CI 1.41-1.90; p<0.0001 in the 
age matched female cohort). The same pattern was observed in men (adjusted ORs in the 
total and age matched cohort OR 1.47; 95% CI 1.34-1.61; p<0.0001 and OR 1.36; 95% CI 
1.21-1.52; p<0.0001).
Study III
Important clinical characteristics are presented in Table 8. IHD was reported in 51% of the 
35 163 patients. The proportion of IHD among patients with diabetes was higher, 62%, than 
in those without, 47%. Previous revascularisation had been performed in 53% and 48% of 
patients with and without diabetes respectively. 
Patients with diabetes with and without IHD
Diabetes patients with IHD were slightly older (75 vs. 74 years), more often men (66 vs. 
57%) with a history of smoking. They, more frequently had reduced LVEF and CKD while 
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Figure 12. Unadjusted and adjusted association between sex and mortality in A) the entire population 
without diabetes (DM); B) in the entire population with DM and in an age-matched sub-cohort. 
Unadjusted and adjusted association between DM and mortality in sex-specific overall, and age-
matched sub-cohorts in C) women and; D) men. 
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associated comorbidities such as atrial fibrillation and idiopathic dilated cardiomyopathy, 
hypertension and pulmonary disease were less common (Table 8). Eighty eight per cent of 
the patients with diabetes without IHD had at least one co-morbidity, increasing to 90% 
if idiopathic dilated cardiomyopathy was added (Table 9). Pharmacological heart failure 
treatment was similar in the diabetes patients with and without IHD. 
Patients with IHD in relation to revascularization
Patients with diabetes without a history of revascularization were older (mean age 77 vs. 73 
years) and considerably more often women (43 vs. 26%) with less comorbidities and less 
reported evidence-based pharmacological heart failure treatment. A similar pattern was seen 
in patients without diabetes.
Mortality
The most serious prognosis was seen in patients with IHD and diabetes, especially in those 
without previous revascularization as illustrated in the age adjusted survival curves in Figures 
13 and 14. Diabetes remained as an independent mortality predictor in all adjustment models 
regardless of the presence of IHD or not. The extensively adjusted HR for mortality imposed 
by diabetes was 1.41 (95% CI 1.33-1.50, p<0.0001) in patients with and 1.30 (95% CI 1.20-
1.41, p<0.0001) in those without IHD. Diabetes remained an independent mortality predictor 
among revascularized IHD patients (adjusted HR 1.36; 95% CI 1.24-1.48, p<0.0001) as 
well as in IHD patients without previous revascularization (HR 1.45; 95% CI 1.33-1.56, 
p<0.0001). 
Table 9. Comorbidity pattern stratified by ischemic vs. non-ischemic aetiology and by diabetes (DM).
No Ischaemic Heart Disease  Ischaemic heart disease
No DM            
n=14 029
DM                     
n=3 243
No DM             
n=12 574
DM               
n=5 317
81% 19% 70% 30%
Variables n (%) n (%) p-value n (%) n (%) p-value
Combinations
HT/AF 9958 (73) 2563 (80) <0.0001 8164 (68) 3852 (76) <0.0001
HT/AF/COPD 10 442 (78) 2639 (85) <0.0001 8675 (73) 3952 (80) <0.0001
HT/AF/COPD/VHD 10 763 (83) 2617 (88) <0.0001 8790 (78) 3903 (83) <0.0001
HT/AF/COPD/VHD/iDCM 11 349 (88) 2674 (90) 0.0004 8836 (79) 3897 (84) <0.0001
HT/AF/COPD/VHD/iDCM/CKD 11 911 (93) 2817 (93) <0.0001 9825 (88) 4294 (92) <0.0001
Abbreviations: AF, Atrial Fibrillation; CKD, Chronic kidney disease; COPD, Chronic Obstructive Pulmonary Disease; HT, 
Hypertension; iDCM, Idiopathic Dilated Cardiomyopathy; DM, Diabetes; VHD, Valvular Heart Disease
n (frequency)  % (percentage).
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Figure 13. Age-adjusted survival curve stratified by diabetes (DM) and ischemic heart disease (IHD).
Su
rv
iv
al
 p
ro
ba
bi
lit
y
Follow-up (years)
1.0
0.8
0.6
0.4
0.2
0 6 82 4
DM, No IHD
DM, IHD
No DM, IHD
No DM, No IHD
Number at risk
No DM, IHD
No DM, No IHD
DM, IHD
DM, No IHD
12574
14029
5317
3243
5791
6943
2391
1565
2158
2535
845
499
537
688
183
119
IHD yes/no & DM yes/no 
Figure 14. Age-adjusted survival in patients with ischemic heart failure stratified by history of 
revascularization (RV) and diabetes (DM).
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Previous revascularization and prognosis
Among patients with diabetes and IHD previous revascularization was associated with 
decreased mortality (adjusted HR 0.82; 95% CI 0.75-0.91, p<0.0001) and this association 
remained after adjusting for the propensity score of previous revascularization (HR 0.87; 
95% CI 0.78-0.96, p<0.0001). Revascularization was associated with an improved prognosis 
even in patients without diabetes (adjusted HR 0.89; 95% CI 0.83-0.96, p<0.0001).
Study IV
Twenty two percent of the 30 696 patients had HFpEF (n=6705), 21% had HFmrEF (n=6483) 
and 57% HFrEF (n=17 509). The prevalence of diabetes was similar in these three groups 
(HFpEF=25%; HFmrEF and HFrEF=24%). Patients with HFpEF were older and more 
often female with hypertension and renal impairment. IHD was more frequent in patients 
with HFmrEF and HFrEF. In diabetes, clinical characteristics differed above all between 
those belonging to HFpEF, compared with the groups with HFmrEF and HFrEF. Pulmonary 
disease was more often seen in HFpEF patients while IHD and a history of revascularization 
was more frequent in patients with HFmrEF and HFrEF. There were no major differences 
between diabetes patients with HFmrEF and HFrEF apart from previous hypertension that 
was more common in HFmrEF than HFrEF and male sex as well as idiopathic dilated 
cardiomyopathy that was more prevalent in HFrEF. 
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Figure 15. Age-adjusted long-term survival in the total population by heart failure entity and diabetes. 
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Study group Number HR / OR (95% CI)
DM vs. No DM DM favourable         DM unfavourable
Study I OR (95% CI)
    Total population 29 634 1.58 (1.47-1.69)
     ≤65 years 6 277 1.61 (1.36-1.92)
     66-80 years 12 050 1.56 (1.42-1.72)
     >80 years 11 132 1.46 (1.31-1.62)
Study II
    Women 9 275 1.72 (1.53-1.94)
    Women age-macthed 5 879 1.64 (1.41-1.90)
    Men 15 906 1.47 (1.34-1.61)
    Men age-matched 10 074 1.36 (1.21-1.52)
Study III HR (95% CI)
    No IHD 12 562 1.30 (1.20-1.41)
    IHD 13 007 1.41 (1.33-1.50)
    IHD, Revasc 6755 1.36 (1.24-1.48)
    IHD, No revasc 6252 1.45 (1.33-1.56)
Study IV
    HFpEF 5 433 1.32 (1.22-1.43)
    HFmrEF 5 310 1.51 (1.39-1.65)
    HFrEF 14 247 1.46 (1.39-1.54)
    LVEF ≥40% 10 743 1.37 (1.22-1.55)
    LVEF <50% 10 235 1.49 (1.36-1.64)
     0.8 1.0 1.5                 2.0
0,8
Figure 16. Independent associations of diabetes (DM) and mortality reported as adjusted Odds Ratios 
(OR) or Hazard Ratios (HR). P<0.0001 accross all four studies. ORs and HRs presented are values 
generated by multiple covariate adjustements as detailed under each study.
HFpEF=LVEF≥50%, HFmrEF=LVEF 40-49%, HFrEF=LVEF<40%.
Impact of diabetes on mortality in the three HF entities
The median follow-up time was four years (range 0-12 years). Total mortality was higher 
and age-adjusted median survival time shorter in the presence of diabetes regardless 
of heart failure entity but with the worst outcome in patients with HFrEF (Figure 15). 
Adjusted HRs associated with diabetes were in HFpEF (1.32; 95% CI 1.22-1.43, p<0.0001), 
HFmrEF (HR 1.51; 95% CI 1.39-1.65, p<0.0001) and HFrEF (HR 1.46; 95% CI 1.39-
1.54, p<0.0001; p for interaction =0.0049). These associations remained after excluding 
patients with a history of valvular disease as well in sub groups with and without IHD. When 
HFpEF and HFmrEF were analysed as one group, i.e. with LVEF ≥40% as a cut point, the 
proportion with diabetes was 24% and the adjusted HR increased to 1.37; 95% CI 1.22-1.55, 
p<0.0001 while if assembling HFmrEF and HFrEF as a group (LVEF <50%), the proportion 
of diabetes was 24% and the adjusted HR of mortality associated with diabetes was 1.49; 
95% CI 1.36-1.64, p<0.0001. When an LVEF ≥50% was used as the reference, the adjusted 
HR for mortality imposed by diabetes increased by deteriorating LVEF. 
A summary of results in Studies I-IV showing HR of mortality imposed by diabetes in 
different sub-groups is outlined in Figure 16.
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GENERAL DISCUSSION
This thesis demonstrates that the combination of heart failure and diabetes is common and 
serious confirming observations in elderly reports and extending them to a contemporary 
everyday life perspective. 
The objective with this thesis was to bring more light into some prevailing gaps in knowledge 
by analysing a nationwide heart failure population provided by the SwedeHF registry from 
different angles. Focus points were to describe i) the contemporary phenotype and prognosis 
in relation to diabetes (Study I); ii) the impact of female sex (Study II); iii) the importance 
of ischaemic-, and non-ischaemic heart failure aetiology (Study III); and iv) the role of heart 
failure with reduced and preserved LVEF (Study IV). 
Diabetes and heart failure – a common combination
Diabetes was reported as present in 24-25% of the total heart failure population (Study 
I), as well as in sub-groups of men and women (Study II), and in HFpEF, HFmrEF and 
HFrEF respectively (Study IV). A particularly high proportion of diabetes, 31%, was seen in 
patients with ischaemic heart failure (Study III). The prevalence of diabetes in heart failure 
populations varies greatly, ranging from 13-47%, depending on the studied population and 
how diabetes was defined.68 Our findings correspond with reports from other chronic, stable 
heart failure populations.71,149,150 as does the proportions of diabetes in ischaemic versus non-
ischaemic heart failure in Study III.71,151 This proportion was lower than the approximately 
40% reported in studies on patients hospitalized for acute, decompensated heart failure.74,152,153 
The higher prevalence of diabetes in these populations may relate to a more serious condition 
comprising a higher risk for deterioration in patients with diabetes.154 Another reason could 
be that the present population emanates from a nationwide registry thereby including the 
whole spectrum of heart failure patients. The latter assumption gets support from the high 
proportion, 58%, of diabetes patients in NYHA class I and II i.e. patient with less severe 
heart failure state. The present broad recruitment base from contemporary, everyday clinical 
praxis makes it reasonable to believe that the present proportion of 24% is representative. 
This does not contradict that more sophisticated screening methods, not the least an oral 
glucose tolerance test, would have disclosed that a higher proportion, maybe as many as two 
thirds of the heart failure patients, would have been diagnosed with dysglycaemia i.e. IGT 
or previously undetected diabetes.10,32,65,66,70,73 It may indeed be considered a drawback not to 
identify such patients since others report that their prognosis is particularly serious.70,73 Other 
reasons that the combination of diabetes and heart failure will further increase is the predicted 
rise in the overall prevalence of diabetes in combination with improved longevity155,19,20, 
improved survival following acute coronary artery syndromes,156 and by means of a better 
multifactorial management.16,157,158 Accordingly, especially patients with diabetes will live 
and develop heart failure to a larger extent than some decades ago.
Prognostic impact of diabetes in heart failure
As described in the introduction, the combination of diabetes and heart failure carries a serious 
prognosis.71,74,78,80,91,96,159 A caveat is that most reports originate from sub-group analyses of 
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trial populations or single hospital registries with a frequently poorly defined definition and 
treatment of diabetes. Thus, it is very likely that these patients represented a selected, not 
too sick and by this reason not representative group. Studies I-IV fills this knowledge gap 
by presenting data from an everyday heart failure population receiving modern care. It was 
observed that diabetes had an independent impact on the prognosis across all studied sub-
groups, increasing the mortality risk with 30-70%. Study I demonstrates that diabetes is 
associated with a compromised survival regardless of age, indeed most pronounced among 
the youngest patients. This pattern was apparent despite a more extensive pharmacological 
treatment in heart failure patients with diabetes and although the distributions of LVEF and 
renal function were similar compared with patients without diabetes. Still the higher NYHA 
classes and NT-proBNP levels in patients with diabetes indicate a more advanced disease state. 
Based on these observations two important pieces of information should be highlighted. First 
that it is important to consider whether diabetes is present or not, at the least in younger heart 
failure patients, since it indicates a need for intensified care and follow-up. Secondly that fur-
ther research and improved therapies are eagerly needed to improve outcome in diabetes pa-
tients with heart failure.
Diabetes in relation to heart failure with different left ventricular function
HFpEF and HFrEF have been considered equally common in heart failure and with a 
comparable prognostic impact.37,38,160 As observed in Studies I and IV the proportions with 
HFpEF, HFmrEF and HFrEF in SwedeHF was uninfluenced by the presence of diabetes or 
not, 22% had HFpEF, increasing to 43% if LVEF cut-off was set at ≥40% instead of ≥50%. 
These findings are in line with other contemporary heart failure populations.37,74 Since none 
of the present patients came from primary care there may have been an underestimation of 
patients with HFpEF, a patient category probably so far less frequently handled in specialist 
care.161 The characteristics of the diabetes patients by heart failure type corresponded with 
reports from the general heart failure population, i.e. patients with HFpEF were more often 
older, women, with a history of hypertension and atrial fibrillation compared with patients 
with HFrEF that to a larger extent were men with a higher prevalence of IHD.30
It seems as if diabetes worsens the prognosis both in HFpEF and HFrEF even if data 
are somewhat sparse and mostly based on retrospective sub-group analyses of selected 
populations.73,162-167 Analyses of HFmrEF with a focus on diabetes are so far lacking. Whether 
diabetes impacts prognosis differently in HFrEF and HFpEF has not been fully explored since 
few studies, if any, compared HFrEF and HFpEF with diabetes as a primary objective.71,96,149 
The present data enabled such comparisons as reported in Study IV. It was noted that 
diabetes had a severe impact on survival irrespective of the type of heart failure. Following 
extensive adjustments this impact was most apparent in HFmrEF, of similar magnitude in 
HFrEF while less pronounced in HFpEF. The present observation contradicts the results from 
CHARM trial in which the relative risk of cardiovascular death or heart failure hospitalization 
conferred by diabetes was more pronounced in HFpEF than HFrEF.71 One reason might be 
a different outcome measure (cardiovascular death and worsening heart failure in CHARM 
vs. total mortality in the present study). Another reason could be differences in the studied 
populations. CHARM recruited younger patients with a less advanced heart failure and 
comorbidity pattern compared with the unselected patients in the present analysis (e.g. mean 
age 67 vs. 76 years in the HFpEF-groups). Moreover, it is possible that the cut-off for HFpEF 
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in CHARM, a LVEF ≥40% vs. ≥50% in the current analysis, resulted in a HFpEF group with 
more severe prognosis in CHARM.71
The impact of diabetes was somewhat increased when the HFmrEF and HFpEF groups were 
combined in Study IV but still lower than the risk conferred by diabetes in HFrEF. In line with 
our observations the Valsartan in Acute Myocardial Infarction trial (VALIANT), including 
patients with ischaemic heart failure also reported that diabetes was associated with a higher 
risk of major cardiovascular events across the range of LVEF with an increasing risk with 
lower LVEF.96 Recent observations from the PARADIGM-HF trial, including LVEF <40%, 
point to a higher hazard of events related to diabetes with deteriorating LVEF.73 The present 
findings do also get support by a Spanish report from the Registro Nacional de Insuficiencia 
Cardiaca (RICA) registry, in which diabetes independently predicted outcome after one year 
with a trend towards higher mortality in HFrEF.149
Study IV provided a diabetes specific description of the newly instituted HFmrEF phenotype. 
It could be concluded that such patients, in the presence of diabetes, resemble patients with 
HFrEF in their clinical characteristics and prognosis. Accordingly, the relevant question 
arises whether the introduction of the entity HFmrEF has any clinical value or if it is a 
matter of academic interest only. Future studies will provide further insights on this topic. 
The observations in Study IV strengthen the evidence that diabetes increases the mortality 
risk across all sub-groups of heart failure. Moreover, it underscores the need of enhanced 
therapy in diabetes patients with heart failure regardless of heart failure entity. 
Underlying mechanisms for the dismal prognosis imposed by diabetes in 
heart failure 
Two major theories behind the dismal prognosis related to diabetes after heart failure deserves 
attention: 1) the heavier burden of associated risk factors and comorbidities in patients with 
diabetes and 2) the existence of a diabetes cardiomyopathy.
Aspects of risk factors and comorbidity
The demographic observations in Studies I and III depict a pattern largely corresponding 
to previous reports i.e. that patients with diabetes were slightly younger but burdened with 
more comorbidities and a higher BMI than those without diabetes. Study I identified IHD 
and hypertension as the most common comorbidities, present in two thirds of the diabetes 
patients. IHD together with reduced renal function were among the most important predictors 
of mortality while the presence of hypertension decreased the risk, probably reflecting intense 
risk factor treatment rather than being protective per se. Study III revealed that 88% of 
diabetes patients without IHD had at least one other comorbidity known to cause heart failure 
among them hypertension, CKD, atrial fibrillation, pulmonary disease and valvular heart 
disease. Importantly several of these comorbidities are manageable with well-established 
therapeutic or preventive strategies underscoring the importance of optimizing preventive 
measures, in which context IHD require some extra attention. 
It is debated if diabetes impacts the prognosis differently in ischaemic and non-ischaemic heart 
failure and previous data provided conflicting results.71,92,151,166,168,169 In Study III diabetes had 
an adverse impact on prognosis irrespective of ischaemic or non-ischaemic aetiology. The 
highest mortality was, however, seen in those with diabetes and ischaemic heart failure, who 
had a 40% risk increase contra 30% in non-ischaemic heart failure. In some previous studies 
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diabetes predicted worse outcome only in patients with ischaemic aetiology,92,166,168 while 
another study noted an association only in non-ischaemic heart failure.169 The interpretation 
of these studies is hampered since the patients were recruited before a wide implementation 
of modern, evidence-based treatment and furthermore most studies were limited to patients 
with LVEF <35%. A sensitivity analysis in Study IV confirmed that the adverse impact of 
diabetes in ischaemic and non-ischaemic heart failure persists in subgroups with different 
LVEF. More contemporary data is provided by the CHARM trial.71 In line with the present 
observations it was noted that diabetes predicted mortality irrespective of ischaemic or non-
ischaemic aetiology including an extended analysis of HFpEF patients. Further support is 
gained from a recent community based multicentre, outpatient study from the UK in which 
diabetes predicted higher mortality irrespective of ischaemic aetiology or not in both HFpEF 
and HFrEF.151 A possible interpretation of the diverging results may be that in contemporary 
heart failure populations subjected to modern evidence-based treatment, as in SwedeHF, 
CHARM and the UK populations, it may be that competing risk of other serious circumstances 
outweighed the impact of diabetes in the past, while a presently improved management of 
concomitant risk factors enhances the impact of diabetes. 
Revascularization was addressed in Study III, which revealed that the prognosis was less 
severe in ischaemic heart failure in the presence of a history of coronary interventions. This 
finding is supported by previous data,170 underlining the importance of ruling out IHD and 
the necessity to carefully investigate the possibility to revascularize patients with diabetes. 
Unfortunately only 50% of eligible patients had been subjected to such interventions, even 
less among the women with diabetes. There are a couple of reasonable explanations for the 
low use of revascularization. The risk of an intervention may have been considered high due 
to the large comorbidity burden and diabetes often causes a more diffuse atherosclerosis 
lessening the opportunity or even willingness to perform a PCI or CABG. It is unlikely 
that these conditions can fully explain such large proportion as 50% of eligible patients. 
Coronary angiography and interventions are freely available in Sweden and convincing 
evidence, favouring revascularization to improve the prognosis in patients with diabetes 
and acute coronary syndromes and multivessel disease, have been provided by the Fragmin 
and Fast Revascularization during InStability in Coronary artery disease (FRISC II) and 
the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optional 
Management of Multivessel Disease (FREEDOM) trials,128,171 It should, however, be 
admitted that none of these trials specifically addressed revascularization in the presence of 
heart failure. A meta-analysis of 3088 patients with left ventricular dysfunction and signs of 
preserved myocardial viability reported on a strong association between revascularization 
and survival.172 Unfortunately, this analysis did not present data from the diabetes sub-
group, but based on present knowledge at least 20-30% of the studied population should 
have diabetes.65,66 The concept of revascularization in patients with established heart failure 
has been challenged by the results of the Surgical Treatment for Ischaemic Heart Failure 
(STICH) trial, which randomized 1212 patients with IHD and left ventricular dysfunction 
to optimal medical therapy alone or optimal medical therapy plus CABG. The initial five-
year follow-up provided neutral results in an intention-to treat analysis, but it was believed 
that a large cross-over undermined the statistical power. This assumption was subsequently 
strengthened by an as-treated analysis.173,174 Indeed, a recently published ten-year follow-
up of STICH (STICH Extension Study; STICHES) reported that CABG was significantly 
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superior to medical therapy alone even when analysed according to the intention-to-treat 
principle providing evidence for the benefits of coronary interventions in heart failure.64 Two 
retrospective studies, applying propensity score analyses, strengthen the benefit of CABG 
over medical therapy in patients with IHD and left ventricular dysfunction.175,176 There is 
nonetheless a gap in knowledge in demand of prospective clinical trials assessing myocardial 
viability with cardiac MRI or PET and the actual impact of revascularization in patients 
with diabetes and ischaemic heart failure.23,177 The on-going Revascularization for Ischaemic 
Ventricular Dysfunction (REVIVED) trial studying the efficacy and safety of PCI in systolic 
heart failure will hopefully provide further insights. Until this and similar trials are available, 
an interpretation of Study III is that there may be a potential benefit of revascularization and 
that it is reasonable to offer all patients with diabetes a thorough investigation not to miss an 
opportunity to revascularize if deemed feasible.
Diabetes cardiomyopathy
Studies I-IV showed that the adverse prognosis imposed by the presence of diabetes in 
heart failure is apparent despite similar treatment and that it persists even after extensive 
adjustment lending support to the hypothesis that a specific diabetes cardiomyopathy may 
be part of the dismal outlook. Still out of all diabetes patients in Study III only 7-10% were 
without a reasonable etiological background. Thus, the present observations do not support 
that a diabetes cardiomyopathy in its pure form,178 is common. This does not contradict 
that something inherent in diabetes contributes to or aggravates the dismal outlook in heart 
failure. As described in the introduction it can be driven by various mechanisms (see page 
21).  They may, however, also be explained by long-standing, poorly controlled hypertension 
or merely be a result of ageing. Another assumption behind the increased heart failure 
prevalence and poor prognosis in patients with diabetes is that the group judged clinically to 
have non-ischaemic heart failure may have a compromised myocardial function secondary to 
silent ischemia or atherosclerosis in small vessels, causing hibernation or stunning, as well as 
scar tissue resulting from silent myocardial infarctions.179,180 
Sex and gender aspects
In general, women are considered protected from premature cardiovascular disease, an 
advantage that is attenuated in the presence of diabetes.15,130,181 It has also been noted that 
women have a survival advantage over men in heart failure.182-184 Study II addressed this 
question and found that diabetes attenuated the survival benefit seen in women compared to 
men with heart failure. This extends the observations in a meta-analysis by Martinez-Selles 
et al,51 based on populations derived from clinical trials to patients in everyday practice. 
In Study II diabetes was a strong risk factor for adverse prognosis in both sexes, although 
we found a slightly higher mortality association in women. Survival within the diabetes 
group did not differ between men and women after consideration of the higher age and more 
frequent CKD in women. These data are in line with a previous report based on a myocardial 
infarction population, indicating no adverse relationship with female sex in itself but rather 
related to more frequent comorbidities in women with diabetes such as IHD, hypertension 
and CKD.185
Women with heart failure and diabetes more often had HFpEF compared with men with 
diabetes. This is consistent with contemporary population-based heart failure registries and 
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reasonably reflects that women develop heart failure at a more advanced age compared with 
men.134,137,186 One main difference, revealed by comparing women with and without diabetes, 
was that women with diabetes more frequently had coexistent IHD, in fact even more 
apparent at ages ≤65 years, where IHD was twice as common. In this context one may say 
that women with diabetes and heart failure had a more ‘male-like’ risk factor profile. Study 
II indicates that the suspected underuse of revascularization in ischaemic heart failure takes 
place irrespective of sex, reported in 43% of the women and 61% of the men with diabetes. 
Moreover, women with diabetes and HFrEF were to a lesser extent prescribed ACEi/ARBs 
but got more diuretics. The most comprehensive evidence-based treatment was seen in men 
with diabetes regardless of age group. This may partially be explained by reduced renal 
function and precautions taken due to higher age in women, but a subconscious disparity 
in management cannot be ruled out as supported by some previous reports134,135,187 but not 
all.137-139
Strengths and limitations
This thesis is based on data from SwedeHF, a nationwide heart failure registry, to the best of 
our knowledge one of the largest of its kind. At the time of data extraction it comprised 47000 
unique patients from 83% of the Swedish hospitals (university and regional hospitals) and 
6% of Swedish primary care clinics, the latter being excluded from the present study. Thus, 
the studied population represents patients under specialist care. The great number of patients 
enabled diabetes focused analyses of pre-specified heart failure sub-populations. Another 
major strength with registry studies is the unselected nature of data i.e. without any restricting 
inclusion and exclusion criteria. This is of particular importance when addressing a sick 
population, as people with diabetes that are often excluded from clinical trials.  
It should be acknowledged that SwedeHF coverage at the time of data extraction was fairly 
low in the early years introducing a bias directed towards heart failure interested centres 
with a probably better than overall managed patient population but possibly also those with 
the most dismal prognosis. This selection decreased over time with expanding numbers 
of engaged clinics. Another selection bias relates to the voluntary reporting of patients 
introducing the risk of missing data. Moreover diagnostic criteria may have varied throughout 
Sweden since SwedeHF did not validate reported data before 2012. As already underlined 
the true proportion of patients with diabetes may have been underestimated since it was 
based on case histories and ongoing treatment only.65,66 Type 1 diabetes was not evaluated 
but comprises a small proportion of all patients with this disease. Although the estimation 
of renal function may vary by different formulas it is not believed that the results in Studies 
I-IV were influenced in any clinically relevant extent. The definition of IHD was expanded 
in Studies III-IV in an attempt to miss as few patients with this diagnosis as possible, 
but information on patient history at the time of inclusion was sometimes incomplete and 
IHD might have been undiagnosed in asymptomatic diabetes patients.179,180 Missing data 
unfortunately compromised the interpretation of prognostically important heart failure 
variables in particular NT-proBNP and to a lesser extent NYHA class. Finally, there was no 
information on diabetes duration and  very limited data on glycaemic control, two factors 
with prognostic implications.82
As always with observational studies like the present the findings should be seen as hypothesis 
generating rather than representing established facts. Still the very large database allowed 
Isabelle Johansson
50
for extensive adjustments including a large number of clinically relevant confounders. In 
addition, when exploring the impact of revascularization in Study III the application of 
a propensity score for treatment in the adjustment model, which to some degree mimics 
randomization although only considering measured variables, strengthened the assumptions 
of the benefit of the coronary interventions. 
Although all-cause mortality is a robust and reliable outcome, we did not have cause-specific 
information on mortality or of other cardiovascular events, which would have been interesting 
to further deepen the understanding behind the high mortality. A median follow-up of 1.9 
years in Studies I-III may appear short, but is mainly an effect of the larger proportion 
of patients included during the most recent part of the study-period. The follow-up period 
ranged between 0 and 8.7 years in study I-III and was in general rather long. Moreover, 
mortality follow-up was extended in Study IV to a median of four years (range 0-12 years). 
If anything this strengthened the association between diabetes and a dismal outcome.
Future perspectives
Although major advances have been made in improving morbidity and mortality in heart 
failure patients, diabetes continues to portend an adverse prognosis more or less without 
exception and without important disparities in the heart failure treatment. Future studies 
should focus on finding ways to improve prognosis for these patients. Such studies should 
for instance include advanced imaging methods of well-defined diabetes populations in 
order to further understand the mechanisms behind diabetes specific myocardial and extra-
myocardial changes. A continued search for novel treatment agents and new treatment targets 
is needed. The beneficial effects with reduced mortality of new glucose-lowering agents such 
as SGLT-2 inhibitors and GLP-1 receptor agonists are of particular interest. Notably, the 
mechanistic explanation of the reduction of heart failure events associated with the SGLT-2 
inhibitor empagliflozin is needed. It would also be of great interest to study if the prevention 
of cardiovascular events with SGLT-2 inhibition can be extended to diabetes patients without 
pre-existing cardiovascular disease as well as to heart failure patients with undiagnosed 
glucose disturbances. Basic research including epigenetic studies can potentially increase the 
understanding of the underlying mechanisms of diabetes cardiomyopathy.
In all day practice efforts are needed to increase the awareness among health care personnel 
of the high prevalence and adverse outcome of the combination of heart failure and diabetes. 
This relates in particular to younger patients, women and patients with ischaemic heart 
disease. Accordingly, a comprehensive risk assessment in patients at elevated risk of diabetes 
and heart failure should be encouraged and the evaluation of intensified treatment and 
follow-up considered. Patients with diabetes and signs of myocardial dysfunction should be 
offered a cardiology consultation for the optimization of their treatment and evaluation of the 
potential need for revascularization.176 Moreover, the prescription of newer glucose lowering 
agents should be encouraged according to already adopted recommendations in international 
management guidelines.9,30
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CONCLUSIONS
Based on the studies comprised in this thesis it can be concluded that:
1. The combination of heart failure and diabetes is common with a diabetes prevalence 
of about 25% both in men and women and irrespective of heart failure entity, increas-
ing to one third in patients with ischaemic heart failure. 
2. Diabetes is associated with a compromised longterm survival, increasing the mortal-
ity risk by 30-70% with the most serious impact in younger patients, in those with 
ischaemic heart disease and in patients with compromised systolic function. 
3. Comorbidites are common in heart failure patients with diabetes. As many as 90% 
have at least one preventable comorbidity of which ischaemic heart disease and hy-
pertension are most frequent. A history of coronary revascularization is associated 
with better outcome but seems underused. 
4. In heart failure, diabetes increases the mortality risk by 70% in women and by 40% 
in men. Age-adjusted survival does not differ between men and women with diabetes. 
Accordingly, the prognostic advantage in women compared with men with heart fail-
ure is attenuated in the presence of diabetes. Women with diabetes and heart failure 
have a risk factor profile resembling that of men with a high prevalence of ischaemic 
heart disease and hypertension. 
5. Diabetes is an independent predictor of mortality in both HFpEF and HFrEF. In dia-
betes, the HFmrEF entity resembles HFrEF in clinical characteristics, risk factor pat-
tern and prognosis, indicating that the introduction of the mid-range entity, HFmrEF, 
may be unnecessary.
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Appendix A. Pre-defined definitions in the Swedish Heart Failure Registry (SwedeHF)
Variables Definition  
i) Heart failure Diagnosed by the attending physician based on guideline 
recommendations at the time of the inclusion. 
ii) NYHA class Classified according to the New York Heart Association classification 
of heart failure based on symptoms and exercise capacity:
   NYHA class I No limitation in physical activities. Ordinary 
physical activity does not cause undue 
fatigue, palpitation or dyspnea.
   NYHA class II Slight limitation of physical activity. 
Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation or 
dyspnea.
   NYHA class III Marked limitation of physical activity. 
Comfortable at rest, but less than ordinary 
activity results in fatigue, palpitation or 
dyspnea.
   NYHA class IV Unable to carry on any physical activity 
without discomfort. Symptoms at rest. If any 
physical activity is undertaken, discomfort is 
increased.
iii) Ischemic heart disease Based on case history, classified as: 
   Yes, verified by coronary angiography
Yes, not verified by coronary angiography
   No  
iv) Idiopathic dilated 
cardiomyopathy
According to the definition in the SwedeHF, patients were assumed 
to have idiopathic dilated cardiomyopathy if signs of dilated 
cardiomyopathy in the absence of ischemic heart disease or 
hypertension as underlying reason.
v) Diabetes Defined as having a history of this diagnosis, specified as type 1 or 
type 2 in combination with glucose lowering treatment in the form of 
life-style advice only or combined with oral glucose-lowering drugs 
and/or insulin.
vi) Revascularization History of coronary artery bypass surgery (CABG) and/or 
Percutaneous Coronary Intervention (PCI)
vii) Hypertension Reported by the attending physician based on case history and/or on-
going blood pressure-lowering therapy.
viii) Ejection Fraction (EF) The most recently estimated Doppler Echocardiography-based 
left ventricular ejection fraction was stratified into four different 
classes: EF ≥ 50, 40-50, 30-39 and <30%. An estimated EF was not 
obligatory for inclusion in the SwedeHF and it was not possible to 
report by which method the EF had been estimated.
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ix) Hemoglobin level (Hb in g/L) Classified as:  
   Normal  Female ≥120, Male ≥130 
   Mild anemia  Female 100-120, Male 110-130 
   Anemia  Female ≤100, Male ≤110
x) HbA1c Expressed according to the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC). Mono S values, used 
until 2010, were converted by the formula HbA1c (IFCC; mmol/mol) 
= 10.45 x HbA1c (Mono S; %) - 10.62
xi) Duration of heart failure According to the definition in the SwedeHF, the time since diagnosis 
or initiation of heart failure treatment, stratified as  ≥ or < 6 months 
duration. 
xii) Atrial fibrillation/flutter According to the definition in the SwedeHF patient history with a 
diagnosis of either atrial fibrillation or flutter.
xiii) Pulmonary disease According to the definition in the SwedeHF diagnosis of, or on-
going/previous treatment for pulmonary disease of importance e.g. 
COPD, asthma, pulmonary tumors, fibrosis, TBC, Sarcoidosis etc. 
Stratified as Yes/No
xiv) Valvular heart disease Case history of present or previous valvular disease of clinical 
importance.   
xv) Myocardial infarction According to the definition in SwedeHF, patient history of diagnosis 
of myocardial infarction or specific, objective signs of changes 
secondary to myocardial infarction such that can be seen on e.g. ECG 
or echocardiography.
FURTHER DEFINITIONS AND CLASSIFICASTIONS IN THE THESIS:
i) eGFR  
(Study I-II)
Estimated by use of the Cockroft-Gault formula142, calculated based 
on serum creatinine taking age, weight and gender into consideration 
according to the following formula: [(140-age) x weight x 1.23 x 
(0.85 if female)] / Creatinine (μmol/L).
Classified as (ml/min/1.73m2): <30, 30-59, 60-89 and >90
ii) eGFR
(Study I-II)
Estimated by use of the MDRD formula143, calculated based on 
serum creatinine, taking age and gender into consideration according 
to the following formula: 186 x [Creatinine (μmol/L)/88.4]-1.154 x age-
0.203 (x 0.742 if female)(x1.212 if black).
Classified as (ml/min): <30, 30-59, 60-89 and >90
iii) Mean arterial pressure Mean arterial pressure = 2/3 Diastolic blood pressure + 1/3 Systolic 
blood pressure
   iv) Pulse pressure Pulse pressure = Systolic blood pressure – Diastolic blood pressure
